

RESEARCH

Open Access



Dopamine-driven increase in IL-1 β in myeloid cells is mediated by differential dopamine receptor expression and exacerbated by HIV

Stephanie M. Matt¹, Rachel Nolan^{1,2}, Samyuktha Manikandan², Yash Agarwal^{1,2}, Breana Channer^{1,2}, Oluwatofunmi Oteju¹, Marzieh Daniali¹, Joanna A. Canagarajah³, Teresa LuPone⁴, Krisna Mompho¹, Kaitlyn Runner¹, Emily Nickoloff-Bybel¹, Benjamin Li⁵, Meng Niu⁶, Johannes C. M. Schlachetzki^{5,7}, Howard S. Fox⁶ and Peter J. Gaskill^{1*}

Abstract

The catecholamine neurotransmitter dopamine is classically known for regulation of central nervous system (CNS) functions such as reward, movement, and cognition. Increasing evidence also indicates that dopamine regulates critical functions in peripheral organs and is an important immunoregulatory factor. We have previously shown that dopamine increases NF- κ B activity, inflammasome activation, and the production of inflammatory cytokines such as IL-1 β in human macrophages. As myeloid lineage cells are central to the initiation and resolution of acute inflammatory responses, dopamine-mediated dysregulation of these functions could both impair the innate immune response and exacerbate chronic inflammation. However, the exact pathways by which dopamine drives myeloid inflammation are not well defined, and studies in both rodent and human systems indicate that dopamine can impact the production of inflammatory mediators through both D1-like dopamine receptors (DRD1, DRD5) and D2-like dopamine receptors (DRD2, DRD3, and DRD4). Therefore, we hypothesized that dopamine-mediated production of IL-1 β in myeloid cells is regulated by the ratio of different dopamine receptors that are activated. Our data in primary human monocyte-derived macrophages (hMDM) indicate that DRD1 expression is necessary for dopamine-mediated increases in IL-1 β , and that changes in the expression of DRD2 and other dopamine receptors can alter the magnitude of the dopamine-mediated increase in IL-1 β . Mature hMDM have a high D1-like to D2-like receptor ratio, which is different relative to monocytes and peripheral blood mononuclear cells (PBMCs). We further confirm in human microglia cell lines that a high ratio of D1-like to D2-like receptors promotes dopamine-induced increases in IL-1 β gene and protein expression using pharmacological inhibition or overexpression of dopamine receptors. RNA-sequencing of dopamine-treated microglia shows that genes encoding functions in IL-1 β signaling pathways, microglia activation, and neurotransmission increased with dopamine treatment. Finally, using HIV as an example of a chronic inflammatory disease that is substantively worsened by comorbid substance use disorders (SUDs) that impact dopaminergic signaling, we show increased effects of dopamine on inflammasome activation and IL-1 β in the presence of HIV in both human macrophages and microglia. These data suggest that use of addictive substances and dopamine-modulating therapeutics could dysregulate the innate inflammatory response and exacerbate

*Correspondence:

Peter J. Gaskill

pjg63@drexel.edu

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.


chronic neuroimmunological conditions like HIV. Thus, a detailed understanding of dopamine-mediated changes in inflammation, in particular pathways regulating IL-1 β , will be critical to effectively tailor medication regimens.

Highlights

- Relative expression of specific dopamine receptors impacts dopamine-induced IL-1 β .
- Dopamine increases IL-1 β in myeloid cells with a high D1/D2 receptor ratio.
- RNA-sequencing of dopamine-treated microglia indicates changes in neuroinflammation.
- Dopamine exacerbates IL-1 β /inflammasome components in HIV-infected myeloid cells.

Graphical Abstract

How Does Dopamine Regulate IL-1 β in Myeloid Cells?



Introduction

Dopamine is an endogenous catecholamine neurotransmitter that has a well-established role in regulating motor control, cognition, motivation, and reward in the central nervous system (CNS). Precise regulation

of dopamine concentrations and bioavailability is crucial for normal CNS function and protection against the development of neurological diseases, such as Parkinson's disease (hypodopaminergic) or schizophrenia (hyperdopaminergic). However, dopamine is not only

found in the CNS, but also has a unique distribution pattern throughout the circulatory system and in many peripheral tissues, where it is important to both neuronal and nonneuronal processes [38, 150, 151]. For example, changes in peripheral dopamine can regulate metabolism, gastrointestinal motility, kidney function, and blood pressure maintenance [6, 24, 63, 71, 96]. In addition, there is increasing recognition that dopamine has a substantial regulatory role in immune cell function in both the CNS and periphery.

Dopaminergic immunomodulation affects innate immunity by modulating the function of myeloid lineage cells such as microglia and macrophages [38], which are the most common immune cells in the CNS [101, 186, 187]. Microglia, which are exposed to high levels of dopamine in specific brain regions such as the nucleus accumbens and striatum, exhibit changes in neuroinflammatory cytokine production, phagocytosis, and formation of extracellular traps [2, 60, 66, 104, 117]. In the periphery, circulating monocytes and differentiated macrophages within tissues that fulfill niche-specific functions can also respond to dopamine. Data show primary human and rodent monocytes/macrophages can take up, store, and produce dopamine [32, 72, 87, 115, 139], and dopamine can modulate myeloid inflammatory signaling. We have previously published that dopamine increases the production of a number of inflammatory cytokines and chemokines in primary human macrophages [172]. These effects, at least in part, are induced by dopamine receptor-mediated activation of NF- κ B, resulting in the induction of its downstream targets including the NLRP3 inflammasome and the inflammatory IL-1 cytokine family including IL-1 β and IL-18 [173]. These data are supported by additional studies showing dopamine receptor activity is inflammatory [66, 163, 164], although other studies have also shown dopamine to have anti-inflammatory effects on NF- κ B and NLRP3 [94, 133, 222, 226, 230].

Fluctuations in extracellular dopamine concentrations could occur in response to the use of dopamine altering therapeutics, or during the use of addictive substances such as stimulants or opioids [7, 29, 105, 129, 130, 201]. Different classes of substances of misuse act via distinct mechanisms, but all addictive substances increase CNS dopamine in vivo, and dopamine signaling plays a significant role in substance use disorders (SUDs) [23, 55, 56, 116, 184]. In both humans and animal models, psychostimulants such as methamphetamine and cocaine promote myeloid neuroinflammation in vivo and in vitro [49, 74, 113, 124, 165]. Stimulant use increases the total area of CNS exposed to aberrant dopamine levels [48, 190, 193, 211, 215], thereby increasing the number of myeloid cells exposed to elevated dopamine concentrations. This

could increase inflammatory cytokine production in myeloid cells in dopamine-rich regions, explaining the inflammatory effects in these regions after drug exposure [31, 36, 74, 174]. Critically, these effects are not observed ex vivo in isolated microglia [36, 74], suggesting that the neuronal release of dopamine in response to these stimulants may be required to mediate the inflammatory effects in myeloid cells.

Most types of immune cells can respond to dopamine through their expression of dopamine receptors and other dopaminergic proteins, which may lead to changes in immune function [38]. Dopamine primarily acts via 5 subtypes of G-protein coupled receptors known as D1-like (DRD1 and DRD5) and D2-like (DRD2, DRD3, and DRD4) dopamine receptors [16]. Nonetheless, the varying affinities of these receptors for dopamine [79] suggests that the ratio of dopamine receptors is important. The balance of D1-like vs. D2-like receptor signaling—and the associated outcomes—could change drastically depending on extracellular dopamine concentrations [145, 179]. Overall, this suggests that dopaminergic immunomodulation could be a common mechanism by which substances of misuse could influence the development of chronic inflammation and risk for neurological disease. In addition, many clinically relevant therapeutics that are dopamine modifying agents, including but not limited to bromocriptine (type 2 diabetes), carbidopa (Parkinson's disease), bupropion (depression), and aripiprazole (schizophrenia) can also impact inflammation [42, 107, 209, 235], potentially through their effects on the dopamine system in immune cells. However, the specific dopamine receptors that drive these effects in human myeloid cells remain inconsistent and poorly understood.

To address this knowledge gap, we examined the role of dopamine receptors in the regulation of IL-1 β in several types of human myeloid cells. In myeloid cells, this cytokine is linked to cell activation and is associated with many human infectious and non-infectious neurological diseases [136, 156, 192, 210]. IL-1 β is a master regulator of inflammation and plays multifaceted roles in the periphery, but the CNS is especially sensitive to IL-1 β signaling because multiple CNS cell types express receptors for IL-1 β [135, 168, 220]. Due to this sensitivity, the secretion of the active form of IL-1 β is tightly regulated by inflammasomes, which are multi-protein complexes that control the maturation and release of IL-1 family cytokines [37, 144]. In the context of dopamine and dopamine-inducing drugs, IL-1 β can be directly increased by substances of misuse through interactions with toll-like receptor 4 (TLR4) [174]. IL-1 β can also uniquely alter the function and expression of dopamine receptors as well as dopamine biosynthesis rate and

storage in vivo and in vitro relative to other cytokines [1, 125, 131, 206], suggesting a greater connection between these two systems than is currently defined. The connections between IL-1 β and the dopaminergic system have primarily been studied in whole brain regions and neuronal populations, leaving the relationship between IL-1 β and the myeloid dopaminergic system unclear. We examined dopamine receptor-mediated IL-1 β regulation in primary human macrophages (hMDM) and microglia, using human microglial cell lines as well as inducible pluripotent stem cell-derived human microglia. Our data in hMDM indicate that while expression of DRD1 is required for dopamine to increase IL-1 β , levels of D2-like receptors can modulate the magnitude of this effect. These findings are supported by studies in microglial cell lines confirming the importance of both types of receptors to IL-1 β production in myeloid cells. RNA sequencing further corroborated our results and showed that dopamine mediates changes in pathways related to IL-1 β signaling in human microglia.

We then examined HIV-infected cells as an example of a neuroimmunological disease that could be exacerbated by SUDs, which are a common comorbidity in people living with HIV (PLWH) [40, 61, 198]. HIV enters the CNS within weeks of initial infection, infecting long-lived myeloid cells such as microglia and CNS-resident macrophages, which are the primary targets for HIV in this compartment [9, 43, 219]. These cells are also major regulators of the innate immune response, driving a chronic, neuroinflammatory state that leads to a variety of neuropathologic effects known as neuroHIV [27, 28, 160].

Even with effective antiretroviral therapy (ART), infected individuals show substantial pathology in dopamine-rich brain regions, including volume decline, increased myeloid cell numbers and activity, and neuronal dysfunction [18, 106, 109]. These data are corroborated by studies in SIV-infected rhesus macaques in which direct increases in CNS dopamine levels via treatment with L-DOPA, methamphetamine, or selegiline significantly enhance neuropathology, increasing viral load, inflammation in dopamine rich brain regions, and the proportion of SIV-infected myeloid cells [51, 52, 143, 162, 171]. We have previously shown that SIV infection alone increases dopamine levels in caudate and frontal cortex, and that selegiline-mediated increases in dopamine in SIV-infected macaques decrease the expression of antiviral genes [64].

Notably, HIV is a prime example of a pathological condition where the role of IL-1 β is well established, as it is elevated in the CNS and serum during HIV and SIV [67, 214, 220, 227, 233]. NLRP3 inflammasomes have also been shown to be upregulated by HIV in CNS and peripheral myeloid cells [214, 220, 232]. Both

inflammasome activation and IL-1 β release are seen in human and rodent macrophages and mixed glial cultures in response to live virus or soluble HIV proteins such as Tat, gp120, and Vpr [39, 44, 114, 214, 220]. This indicates that productive viral replication of cells is not a requirement of induction of this inflammation. As we hypothesized, the data indicate that the effects of dopamine on IL-1 β and inflammasome components are altered in the presence of HIV infection. These findings suggest an unexplored mechanism underlying dopamine-mediated myeloid cell activation associated with signaling and processing of IL-1 β , and provide a potential target for the development of therapeutics aimed at managing inflammation in disease.

Methods

Reagents

DMEM (cat # 10569044) and RPMI-1640 (cat # 11875119) medium, sodium pyruvate (cat # 11360070), trypsin, and penicillin/streptomycin (P/S) (cat # 15140163) were from Invitrogen (ThermoFisher, Carlsbad, CA, USA). Bovine serum albumin (BSA) (cat # BP1600100), glycine (cat # G48500), 4% Paraformaldehyde solution (cat # AAJ19943K2), blasticidin (cat # R21001), Zeocin (cat # R25001), and calcium phosphate transfection kits (cat # K278001) were from Fisher Scientific (Waltham, MA, USA). Hydroxyethyl piperazineethanesulfonic acid (HEPES) (cat # BP2991), Tween (cat # NC0689073), dimethyl sulfoxide (DMSO) (cat # 472301), Poly I:C (cat # P1530), and dopamine hydrochloride (cat # H8502) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Fetal calf serum (FBS) was from Corning (cat # MT35010CV), human AB serum was from Gemini Bio-Products (cat # 100-512), and PEG-It Virus Precipitation Solution (cat # LV825A-1) was from System Biosciences. Macrophage colony stimulating factor (M-CSF) (cat # 300-25), IL-34 (cat # 200-34), and TGF- β 1 (cat # 100-21) were from Peprotech (Rocky Hill, NJ, USA). TaqMan Fast Universal Master Mix, and PCR assay probes for DRD1-5 (Hs00265245_s1, Hs00241436_m1, Hs00364455_m1, Hs00609526_m1, Hs00361234_s1), IL-1 β (Hs01555410_m1), NLRP3 (Hs00918082_m1), NLRC4 (Hs00368367_m1), AIM2 (Hs00915710_m1), NLRP1 (Hs00248187_m1), NLRC5 (Hs01072123_m1), IL-18 (Hs01038788_m1), IL1rn (Hs00893626_m1), Pycard (Hs01547324_gH), Casp1 (Hs00354836_m1), and 18 s (4319413E) genes were purchased from Applied Biosystems (ThermoFisher, Waltham, MA, USA). Flupentixol dihydrochloride (cat # 4057/50) was from R&D Systems (Minneapolis, MN, USA), and was diluted to a stock concentration of 100 mM in dH₂O and aliquoted and stored at -20 °C until use.

Dopamine hydrochloride (DA) was resuspended in dH₂O at a stock concentration of 10 mM that was then aliquoted and frozen at -20°C for 2 months or until use, whichever occurred first. All dopamine preparations and treatments were performed in the dark using 10^{-6} M dopamine unless otherwise stated, with dopamine treatment occurring immediately after thawing the dopamine. This concentration of dopamine was chosen to model the amount of dopamine to which macrophages in the CNS could be exposed to during stimulant use [150, 151]. Although dopamine has been shown to oxidize and form cytotoxic reactive oxygen species in some in vitro conditions [20, 154], previous data shows it is not associated with IL-1 β production [173] and in our current studies we show that 10^{-6} M dopamine is not cytotoxic to macrophages in our culture system (Supplementary Fig. 1).

Isolation of primary peripheral blood mononuclear cells, monocytes, and generation of macrophages from human donors

Human peripheral blood mononuclear cells (PBMC) were separated from blood obtained from de-identified healthy donors from multiple sites including the New York Blood Center (Long Island City, NY, USA), University of Pennsylvania Human Immunology Core (Philadelphia, PA, USA), BioIVT (Westbury, NY, USA), and the Comprehensive NeuroHIV Center (CNHC) and Clinical and Translational Research Support Core (CNHC/CTRSC) Cohort at Drexel University College of Medicine (Philadelphia, PA, USA) by Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA) gradient centrifugation. PBMC were isolated and 5 million were set aside for subsequent mRNA analysis. Another 10 million PBMC were used to obtain pure, unlabeled monocytes by negative selection using the human Pan Monocyte Isolation kit (Miltenyi). Monocytes were set aside for subsequent qPCR. The remaining PBMC were matured into monocyte-derived macrophages (hMDM) using adherence isolation. Cells were cultured for 6–7 days in macrophage media (RPMI-1640 with 10% FBS, 5% human AB serum, 10 mM HEPES, 1% P/S, and 10 ng/mL M-CSF). A subset of cells from Fig. 5 were cultured in DMEM with 10% FBS, 5% human AB serum, 10 mM HEPES, 1% P/S, and 10 ng/mL M-CSF, and there was no significant difference relative to DMEM cultured samples (data not shown).

Limited, de-identified demographic information (age, gender, ethnicity, blood type and cytomegalovirus (CMV) status) was obtained as we have previously described [152], although all data categories were not available for each donor. The entire data set of donors was used to determine the relative expression of dopamine receptors, but not all demographic information was disclosed for every donor so not every donor was able to be used for

every correlation. Dopamine receptor expression from subsets of these donors have been previously published [152, 170, 172]), but this study combines donors from previous studies as well as 46 new donors across the current experiments. Use of the entire data set enables more robust examination of the correlations between IL-1 β production and dopamine receptor expression due to the variability inherent in primary human macrophages.

Culture of C06 and C20 microglial cells

The C06 and C20 human microglial cell lines were a generous gift from the Karn laboratory (Case Western Reserve University) and details pertaining to the generation of these cell lines has been previously described [77]. Briefly, human microglia were obtained from ScienCell Research Laboratories, Carlsbad, CA (Cat# HM1900) and then immortalized using simian virus 40 large T antigen and hTERT [77]. These cells were maintained in 150-cm² tissue culture flasks (Falcon) in DMEM supplemented with 5% FBS, 10 mM HEPES, 1% P/S, and 1% sodium pyruvate at 37°C in a humidified incubator under 5% CO₂.

Differentiation and culture of human, iPSC-derived microglia

The inducible pluripotent stem cell-derived microglia (iMicroglia) were generated from common myeloid progenitors obtained from the Human Pluripotent Stem Cell Core at the Children's Hospital of Philadelphia (CHOP) as we have done previously [152]. This process uses an 11-day differentiation protocol that produces ramified cells that are susceptible to HIV infection and express the microglial markers CX₃CR₁, IBA1, TMEM119, and P2RY12, with very similar gene expression to human microglia [195]. The cells used in this study were derived from the WT6 iPSC cell line. These cells were differentiated and maintained in RPMI-1640 supplemented with 1% FBS, 0.1% P/S, and IL-34 (100 ng/mL), M-CSF (25 ng/mL), and TGF- β 1 (50 ng/mL) at 37°C in a humidified incubator under 5% CO₂. Cytokines were added fresh with each media change. iMicroglia were cultured in glass bottomed petri dishes (Fluorodish, World Precision Instruments) or Cellbind plates (6 or 96 well, Fisher Scientific) depending on the experiment.

Lentiviral production and generation of C20.TetR.DRD2 microglial cell lines

The TetR and DRD2 lentivirus was made via calcium phosphate transduction of LentiX cells. TetR and helper plasmids and cell lines were a generous gift from Dr. Edward Hartsoogh (Drexel). Briefly, 3 mg/mL of the PLP1, PLP2, PLPVSVG and TR (for TetR lines) or DRD2 (for DRD2 lines) plasmids were mixed with Ca²⁺. The

solution was then added dropwise to 2X HBS and the resulting mix was added to the plate of LentiX cells at 70–80% confluency. After 4 days, supernatant was collected and incubated with 4X PEG-It solution for 24 h. The supernatant-PEG-It mix was then spun down and the resulting viral pellet was resuspended in 150 mL PBS and stored at -80°C until further use.

Wild-type C20 cells were transduced with 20 mL concentrated TetR lentivirus for 48 h. Following transduction, the cells were re-plated in 10 cm dishes and treated with 8 mg/mL blasticidin for 4 days. The concentration was then dropped to 5 mg/mL blasticidin and media was refreshed every 3 days for approximately 3 weeks, until distinct colonies had formed. Individual colonies were picked and plated in individual wells of a 12-well plate and grown in C20 media without selection antibiotics until confluent. The cells were then re-plated in a 75cm² flask and expanded. Successful transduction of 6 distinct colonies was confirmed using Western blotting. The clone with the highest expression, labeled C20.TetR #2, was used moving forward. The C20.TetR #2 cells were plated and transduced with DRD2 lentivirus at 20 mL for 72 h, moved to 10 cm dishes and then selected for using in selection media (C20 media plus 300 mg/mL Zeocin) for approximately 4 weeks as described above. Colonies were then picked and expanded until there were enough cells to be frozen down and stored for further experiments.

Viral stocks

Viral stocks of HIV_{ADA} were generated by infecting CEM-SS cells with HIV_{ADA}, a blood derived, R5-tropic strain of HIV [84], as we have done previously [80, 152]. Briefly, CEM-SS cells cultured in T175 flasks were infected with a single tube of HIV_{ADA} stock, then cultured until syncytia started to form, changing media every 3–4 days. For the stocks used in this study, syncytia began to form at 17 days post infection, so cell-free supernatants were collected daily at 18 to 41 days post-infection. Each stock was centrifuged at 1200 × g to pellet cells and debris, then moved to a fresh conical vial, aliquoted in 1 mL aliquots and stored at -80°C for use as viral stocks. Stock concentration was determined by quantifying the amount of p24-Gag per mL, using an HIV p24 (high sensitivity) AlphaLISA Detection kit (Revvity, Waltham, MA).

Cell viability assays

Primary hMDM were plated at 15,000 cells/well in a 96-well black-walled plate (NUNC, ThermoFisher Scientific) and treated with a range of concentrations of dopamine (1×10^{-10} M to 5×10^{-4} M) in duplicate wells for 24 h. After treatment, supernatants were collected, and cells were stained with LIVE/DEAD Cell Imaging

Kit (ThermoFisher Scientific cat # R37601) according to manufacturer's instructions. Cells were then imaged using the Cellomics CellInsight CX7 HCS Platform at 20× magnification and 20 fields per well. After images were acquired on the CX7, quantitative analysis was performed, to identify live and dead macrophages using HCS Studio software, using the Thermo Scientific Cellomics Colocalization Bioapplication, and specific parameters are included in Supplementary Table 1. These images had donor-specific manual alterations in Image Settings to correct any background. As an example for one representative donor, the live (green) stain was gated by excluding border objects, thresholding (fixed) at 500, segmentation (intensity) at 500, object area 854.84–7746.16 to eliminate small non-cellular debris, object variant intensity 7.52–65,535 (Supplementary Table 1). The dead (red) stain was gated by excluding border objects, thresholding (fixed) at 2000, segmentation (intensity) 28, and object area 265.28 to 6653.4 to exclude small debris. Cell level data was taken at Object Count Ch2 and used to calculate total number of cells, live cells, dead cells and %viability. To examine the initial health of the hMDM cultures pre-experiment, a time 0 was added to a subset of donors.

To provide a confirmatory evaluation of cell viability, collected supernatants were quantified for LDH release, using the CyQUANT[™] LDH Cytotoxicity Assay (ThermoFisher Scientific # C20301). Supernatants from time 0 were used as a spontaneous LDH release control to quantify change in LDH over 24 h in vehicle and treated wells. Cellular lysates using M-PER (ThermoFisher Scientific # PI78501) were used to identify the maximum LDH release possible. 50 µL of each condition were loaded in triplicate wells on 96-well plates and incubated with 50 µL of reaction mixture (LDH substrate mix, and assay buffer) for 30 min at 25 °C in the dark. Stop solution (50 mL) was added to each well and then absorbance values at 490 nm and 680 nm were taken on a spectrophotometer. Viability was calculated by first calculating the % cytotoxicity using the equation $\frac{\text{Sample absorbance} - \text{Spontaneous LDH release}}{\text{Maximum LDH release} - \text{Spontaneous LDH release}} \times 100$. This percentage was then subtracted from 100% to obtain the %viability.

Quantitative RT-PCR

Total RNA was extracted from cells using Trizol, the RNeasy Mini Plus[™] kit (Qiagen), or the Quick-DNA/RNA Microprep Plus Kit (Zymo), and RNA quantity and purity were determined by a NanoDropOne spectrophotometer (Nanodrop Technologies). RNA (1 µg) was used to synthesize cDNA using the high-capacity reverse transcriptase cDNA synthesis kit (Abcam). All dopamine receptor subtypes (DRD1-DRD5), IL-1β, NLRP3, NLRP1,




Fig. 1 Dopamine-mediated increase in IL-1 β production in primary macrophages varies with expression of dopamine receptor subtypes. Primary human monocyte-derived macrophages (hMDM) were treated for 24 h with 10^{-6} M dopamine. Lysates were collected and analyzed for IL-1 β using AlphaLISAs. Results were normalized to protein concentration. qPCR detected mRNA for all subtypes of dopamine receptors (DRD1, DRD2, DRD3, DRD4 and DRD5). In our 42 donors, which together significantly respond to dopamine and increase IL-1 β production (**A**), most express DRD1 and DRD2, whereas a much smaller proportion express DRD3 and DRD4 (**B**). The connection between dopamine receptors and IL-1 β was determined by analysis of IL-1 β levels in hMDM that did or did not express (**C**) DRD1, (**D**) DRD2, (**E**) DRD3, and (**F**) DRD4. Although all express DRD5, we examined DRD5's impact on dopamine-induced IL-1 β production by splitting expression into quartiles: low, medium, high, and highest expression (**G**). Significance was determined using Wilcoxon and Mann–Whitney tests, * $p < 0.05$, *** $p < 0.001$, and **** $p < 0.0001$

NLRC5, NLRC4, AIM2, IL-18, IL-1 α , PYCARD, CASP1, and the housekeeping gene 18 s were amplified from cDNA by quantitative PCR (qPCR) on a QuantStudio 7 using gene-specific primers. In Figs. 1, 2, 3, all dopamine receptor mRNA was examined in every sample in these experiments. Any sample in which a dopamine receptor Ct (cycle threshold) value was greater than 37, we regarded it as not detectable (no expression).

RNA-seq library preparation

RNA-seq library preparation was performed as described elsewhere and as follows [132]. RNA isolation from C20 cells was carried out as described above and total RNA was enriched in poly-A tailed RNA transcripts by double incubation with Oligo d(T) Magnetic Beads (NEB, S1419S) and fragmented for 9 min at 94 °C in 2X Superscript III first-strand buffer containing 10 mM DTT (Invitrogen, #P2325). The 10 μ L of fragmented RNA was added to 0.5 μ L of Random primers

(Invitrogen, #48190011), 0.5 μ L of Oligo d(T) primer (Invitrogen, #18418020), 0.5 μ L of SUPERase inhibitor (Ambion, #AM2696), 1 μ L of 10 mM dNTPs and incubated at 50 °C for 3 min. Then, 5.8 μ L of water, 1 μ L of 10 mM DTT, 0.1 μ L of 2 μ g/ μ L Actinomycin D (Sigma, #A1410), 0.2 μ L of 1% Tween-20 (Sigma) and 0.5 μ L of SuperScript III (Invitrogen, #ThermoFisher 18,080,044) was added to the mix. Reverse-transcription (RT) reaction was performed at 25 °C for 10 min followed by 50 °C for 50 min. RT product was purified with RNAClean XP (Beckman Coulter, #A63987) and eluted in 10 μ L in 0.01% Tween 20. The RNA-cDNA complex was then added to 1.5 μ L of 10X Blue Buffer (Enzymatics, #B0110-L), 1.1 μ L of dUTP mix (10 mM dATP, dCTP, dGTP and 20 mM dUTP), 0.2 μ L of 5 μ /mL RNaseH (Enzymatics, #Y9220L), 1 μ L of 10 U/ μ L DNA polymerase I (Enzymatics, #P7050L), 0.15 μ L of 1% Tween 20 and 1.05 μ L of nuclease free water; and incubated at 16 °C for 2.5 h or overnight. The




Fig. 2 Dopamine receptor expression levels in primary human myeloid cells change with maturation. Primary human peripheral blood mononuclear cells (PBMCs), monocytes, and monocyte-derived macrophages (hMDM) were collected for subsequent mRNA analysis. 19 of these donors were paired across the three cell types. **A** qPCR detected mRNA for all subtypes of dopamine receptors (DRD1, DRD2, DRD3, DRD4 and DRD5) that were differentially expressed in these cell types (N = 33–42). **B** Using a D1-like to D2-like ratio (DRD1 + DRD5 / (DRD2 + DRD3 + DRD4)), hMDM had a significantly higher ratio compared to monocytes or PBMCs. Significance was determined using Kruskal–Wallis tests and post-hocs with Dunn’s multiple comparisons, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$

resulting dsDNA product was purified using 28 μ L of Sera-Mag SpeedBeads Magnetic Carboxylate (ThermoFisher, #65152105050250) diluted in 20% PEG8000, 2.5 M NaCl to a final 13% PEG concentration, washed twice with 80% EtOH, air dry and eluted in 40 μ L of 0.05% Tween 20. The purified 40 μ L of dsDNA was end-repaired by blunting followed by A-tailing and adapter ligation as described elsewhere [100] using BIOO Barcodes (BIOO Scientific, #514104), 0.33 μ L 1% Tween 20 and 0.5 μ L T4 DNA ligase HC (Enzymatics, #L6030-HC-L). Libraries were amplified by PCR for 11–15 cycles using Solexa IGA and Solexa IGB primers (AATGATACGGCGACCACCGA and CAAGCAGAA GACGGCATACTGA, respectively), and size selected for fragments (200–500 bp) by gel extraction (10% TBE gels, Life Technologies EC62752BOX). Eluted libraries were quantified using a Qubit dsDNA HS Assay Kit and sequenced on a NovaSeq 6000 (Illumina, San Diego, California).

Analysis of RNA-Seq

To generate the read count matrix, we used nf-core RNAseq pipeline version 3.10.1 with the FASTQ sequencing files as input [57, 97]. The reads are filtered and mapped to a customized reference genome which combines hg38 and NC_001802.1 using STAR aligner [59]. The resulting count matrix is used as the input for Partek® Flow® software for differential expression

analysis. We used DESeq2 to conduct the differential expression analysis, and the results are filtered with $FDR < 0.05$ [138]. For functional analysis, we used IPA on the filtered gene lists (QIAGEN Inc., <https://digit.alinsights.qiagen.com/IPA>).

IL-1 β production and caspase-1 secretion assays

Primary hMDM were cultured at 9.5×10^4 cells per well in 48-well plates (BD Falcon), C06/C20 microglia were cultured at 1×10^6 cells per well in 6-well plates (BD Falcon), and iMicroglia were cultured at 5×10^4 cells per well in 96-well plates (CellBind). Macrophages (hMDM) were treated for 24 h [172] and microglia (C06/C20 and iMicroglia) were treated for 4 h with 10^{-6} M dopamine. Treatment with LPS (10 ng/mL) was used as a positive control. At 30 min (hMDM) or 1 h (C06/C20 and iMicroglia) prior to supernatant collection, cells were stimulated with ATP (2.5 mM) to induce inflammasome activation, and lysates were collected for the analysis of IL-1 β production while supernatants were collected for the analysis of active caspase-1. Lysates were analyzed for IL-1 β using AlphaLISAs performed according to the manufacturer’s protocol (Revvity). We used a 96-micro-well plate (Revvity, #6002290) and a sample volume of 10 μ L. The plate was read using an EnSpire™ plate reader (Revvity). Interpolated values were determined from a 12-point standard slope according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose–response curve with variable slope). Those values




Fig. 3 Dopamine receptor-dependent effects on IL-1 β expression in human microglia. Dopamine receptor transcripts were measured by qPCR. C06 and C20 microglia express DRD1, DRD2, and DRD5 mRNA. **A** In C06 microglia, there was significantly higher DRD2 expression compared to the D1-like receptors, and in **B** C20 microglia, there was significantly higher expression of the D1-like receptors compared to DRD2. **C** C06 and **D** C20 microglia were treated with dopamine (10^{-6} M) or LPS (10 ng/mL) as a positive control for 3 h and examined for IL-1 β mRNA. There was no effect in C06 microglia, but in C20 microglia, dopamine significantly increased IL-1 β mRNA. **E** C06 and **F** C20 microglia were treated with dopamine (10^{-6} M) or poly i:c (10 μ g/mL) as a positive control for 4 h, then lysates were collected and examined for IL-1 β production by AlphaLISA. There was no effect in C06 microglia. However, in C20 microglia dopamine significantly increased IL-1 β production. **G** C06 and **H** C20 microglia were pretreated with flupentixol (Flux, 10^{-6} M) or vehicle for 30 min in the presence of absence of 3 h dopamine (DA, 10^{-6} M) treatment and examined for IL-1 β mRNA. There was no effect of treatment on C06 microglia, but in C20 microglia Flux significantly blocked the DA-mediated increase in IL-1 β . Significance was determined by paired t-tests, Wilcoxon tests, Kruskal–Wallis tests, post-hoc with Dunn’s multiple comparisons, and a two-way mixed effects model and post-hoc with Tukey’s multiple comparisons, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. ND = not detected

were normalized to the protein concentration of hMDM lysates, and protein concentrations were quantified using a Bicinchoninic acid assay (BCA) with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). This was done to normalize output by the number of collected cells. The limit of detection for the IL-1 β AlphaLISAs was 0.6 pg/mL. Cells that did not respond to LPS with at least a 1.5-fold increase in IL-1 β were excluded from the analysis. The caspase-1 concentration in supernatants was determined via Quantikine® ELISA performed according to the manufacturer's protocol, and the limit of detection for this assay was 0.68 pg/mL (R&D systems, Minneapolis, MN, USA).

Immunofluorescence

For immunofluorescent staining of microglial markers, C20 cells were cultured in 96-well glass-like polymer plates (P96-1.5P, Cellvis) at a density of 5000 cells per well. Cells reached optimal confluency after 4 days, at which point cells were fixed with 4% PFA at room temperature for 10 min, permeabilized, and incubated with blocking buffer (1% BSA, 0.1% Tween 20, and 22.52 mg/mL glycine in 1X PBS) at room temperature for 30 min. After blocking, cells were then incubated overnight at 4 °C with a P2RY12 primary antibody (1:100, 702516, Thermo Fisher) or TMEM119 primary antibody (1:50, PA5119902, Thermo Fisher) diluted in blocking buffer. Following the primary incubation, the C20 cells were incubated with an Alexa Fluor 488 secondary antibody (A-11001, Fisher Scientific) diluted in blocking buffer for 1 h at room temperature. All cells were stained with DAPI (0.2 μ g/mL, D1306, Thermo Fisher) for 10 min and preserved in 1X PBS. High-content imaging of stained cells was performed using the Cellomics CX7 platform, capturing 20 fields per well at 20 $\times$ magnification.

To prepare iMicroglia for immunofluorescent staining, cells were cultured in glass-bottomed petri dishes (Fluodish, World Precision Instruments) coated with poly-D-lysine (0.1 mg/mL, P6407, Sigma-Aldrich) at a density of 300,000 cells per dish. The cells were either mock-infected or infected with HIV, in the presence or absence of 10⁻⁶ M dopamine, for 7 days. After the treatment, the cells were fixed with 4% PFA at room temperature for 10 min, permeabilized, and incubated with blocking buffer (1% BSA, 0.1% Tween 20, and 22.52 mg/mL glycine in 1X PBS) at room temperature for 30 min. Subsequently, the cells were incubated overnight at 4 °C with an anti-HIV-1 p24 monoclonal (AG3.0) primary antibody (4 μ L/mL) (NIH HIV Reagent Program catalog# 4121) or P2RY12 primary antibody (1:100, 702516, Thermo Fisher) or TMEM119 primary antibody (1:50, PA5119902, Thermo Fisher) or Iba1 (10 μ g/mL, PA5121836, Thermo Fisher) prepared in blocking buffer.

After the primary incubation, iMicroglia were incubated with an Alexa Fluor 488 secondary antibody (A-11001, Fisher Scientific) prepared in blocking buffer for 1 h at room temperature. Afterwards, all cells were stained with CellMask Deep Red (250 ng/mL, catalog # C10046 Thermo Fisher) for 10 min and cover slipped with Slow-Fade™ Glass Soft-set Antifade Mountant, with DAPI (catalog # S36920 Thermo Fisher). iMicroglia images were acquired at 60X using an Olympus FV3000 confocal laser scanning microscope.

Western blotting

For Western blot analysis, hMDM were cultured at 9.5 $\times$ 10⁵ cells per well in 6-well plates (Thermo Fisher). The cells were mock-infected or infected with HIV for 7 days, and after 7 days of infection, treated with vehicle (H₂O) or 10⁻⁶ M dopamine for 3 h. Cells were lysed using lysis buffer from the Quick-DNA/RNA Microprep Plus Kit (D7005, Zymo Research), and flow-through protein was separated according to the manufacturer's instructions. Cold acetone was added to the flow-through protein in a 4:1 ratio and the mixture was incubated on ice for 30 min. Then samples were centrifuged at 13,000 RPM for 10 min at 4 °C. Following aspiration of the supernatant, samples were washed in 400 μ L of molecular-grade 100% EtOH. The samples were again centrifuged at 13,000 RPM for 1 min at 4 °C, supernatants were removed and then protein pellets were dissolved in mammalian protein extraction reagent (M-PER, Thermo Fisher Scientific, Waltham, MA), containing 1% Halt Protease and Phosphatase Inhibitor cocktail and 1% EDTA (Thermo Fisher Scientific, Waltham, MA). Lysates were sonicated with a Q125 sonicator (Qsonica, Newtown, CT) at 25% power for 5 s and stored at 4 °C for 1–7 days. Subsequently, protein concentrations were quantified using a Bicinchoninic acid assay (BCA) with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). The lysates were diluted to a concentration of 1.5 μ g/ μ L and stored at – 80 °C until analyzed by Western blot.

On the day of the Western blot, samples were thawed at RT, and mixed with 4X protein loading buffer (Licor Biosciences, Lincoln, NE) containing 10% 2-Mercaptoethanol (BME), then boiled at 95 °C for 10 min. Protein lysates were then separated by gel electrophoresis on Bolt Bis–Tris Plus gradient 4–12% precast gels in MOPS/SDS running buffer in a Mini gel tank (Life Technologies, Carlsbad CA). Separation was performed for 60 min at 150 V, and then proteins were transferred to an Immobilon PVDF membrane (EMD Millipore, Temecula, CA) at 25 V for 90 min. To generate an internal loading control, membranes were imaged after treatment with Revert Total Protein Stain (LI-COR Biosciences, Lincoln, NE) according to the manufacturer's instructions. Revert stain was then removed and

then membranes were blocked in 5% BSA for 2 h at RT and then incubated overnight at 4 °C in either anti-NLRP3 antibody (15101S, 1:1000 in 5% BSA, Cell Signaling), anti-NLRC4 antibody (12421, 1:1000 in 5% BSA, Cell Signaling) or anti-AIM2 antibody (

MA5-38442, 1:1000 in 5% BSA, Thermo Fisher Scientific). Following primary antibody incubation overnight, blots were washed in TBS with 0.1% Tween, stained with anti-rabbit IgG HRP linked antibody (CST 7074, 1:3000 in 5% milk) for NLRP3 and NLRC4 or anti-mouse IgG HRP linked antibody (CST 7076, 1:3000 in 5% milk) for AIM2, and incubated at RT for 1 h. After the secondary incubation, blots were washed and incubated in Supersignal West Pico PLUS plus Chemiluminescent Substrate (2 mL, 30 s, ThermoFisher, 34580). Blots were imaged using an Odyssey Fc Imaging System and analyzed using Image Studio Lite (Licor Biosciences, Lincoln, NE). Target bands were normalized to the total protein stain, and then each condition was compared to the mean expression of the vehicle controls to determine the fold change in expression.

Statistics

Prior to analysis, all data were normalized to the mean of the vehicle treated condition. Specifically, all raw values of the vehicle condition from our experimental assays were averaged and each raw value from every condition was divided by this vehicle mean. To determine the appropriate statistical tests, data sets were evaluated by analysis of skewness and evaluation of normality and lognormality to determine the distribution of the data. Extreme data points presumed to be technical outliers were identified via ROUT test ($Q=0.1\%$) and removed from analysis. Statistical analysis of gene expression data was performed on data normalized to $2^{-\Delta CT}$. *Post-hoc* analyses were performed when appropriate. While positive controls are shown on the same graph as dopamine-mediated changes, they were not included in ANOVA analyses analyzing the impact of dopamine in most figures. The separate tests performed on the positive controls are denoted using the @ sign, rather than the * used to show significance in the analyses of dopamine-mediated changes. All data analysis was performed using GraphPad Prism 10.0 (Graphpad, La Jolla, CA). $p < 0.05$ was considered significant.

Data availability

The RNA-seq data from this study has been deposited in the GEO database, accession # GSE273395.

Results

Dopamine-mediated increase in IL-1 β production in primary macrophages varies with expression of dopamine receptor subtypes

Our prior work on dopamine-mediated regulation of cytokine production in primary human monocyte-derived macrophages (hMDM) [172, 173] suggests a pivotal role of dopamine receptor subtype expression on cytokine production. Across hMDM examined from 42 healthy donors, we observed a significant increase in IL-1 β protein production in response to 10^{-6} M dopamine (Fig. 1A, Wilcoxon test, $n=42$, $*p=0.0276$, sum of (+, -) ranks 627, - 276). Within this population, hMDM from 27 donors (65%) showed a greater than 20% increase in IL-1 β , while cells from 15 donors showed an increase lower than 20%. Next, we determined the expression of all dopamine receptors in hMDM via qPCR. From these 42 donors, most hMDM express DRD1 (71.43%) and DRD2 (64.29%), whereas DRD3 (21.43%) and DRD4 (30.95%) are expressed on a much smaller proportion of hMDM (Fig. 1B). DRD5 mRNA was detected in all samples.

Next, we examined whether differential dopamine receptor expression impacts IL-1 β production. We detected a significant dopamine-mediated increase in IL-1 β production in hMDM with detectable DRD1 expression compared to samples with non-detectable DRD1 mRNA (Fig. 1C, Wilcoxon tests, with DRD1, $n=30$, $***p=0.0009$, sum of (+, -) ranks 388, - 77; without DRD1, $n=12$, $p=0.4697$, sum of (+, -) ranks 49, - 29). In contrast, dopamine significantly increased IL-1 β production in hMDM both with and without DRD2 detectable expression. However, in hMDM without DRD2, the magnitude of the dopamine-mediated increase was significantly greater than in hMDM with DRD2 (Fig. 1D, Wilcoxon tests, with DRD2, $n=27$, $*p=0.0260$, sum of (+, -) ranks 281, - 97; without DRD2, $n=15$, $***p < 0.0001$, sum of (+, -) ranks 120, 0; Mann-Whitney test, $n=15-27$, $*p=0.0277$, sum of (Dopamine-induced IL-1 β D1 vs No D1) ranks 497, 406, $U=119$). The effects of DRD3 expression were similar to those found with DRD2, with dopamine-mediated increases in IL-1 β in hMDM both with and without detectable DRD3, although this was only significant in hMDM without DRD3 (Fig. 1E, Wilcoxon tests, with DRD3, $n=9$, $p=0.0742$, sum of (+, -) ranks 38, - 7; without DRD3, $n=33$, $***p < 0.0001$, sum of (+, -) ranks 537, - 24). Dopamine-mediated IL-1 β production was dependent on detectable DRD4 expression, like DRD1 (Fig. 1F, Wilcoxon tests, with DRD4, $n=13$, $*p=0.0398$, sum of (+, -) ranks 75, - 16; without DRD4, $n=29$, $p=0.8148$, sum of (+, -) ranks 229, - 206). Finally, while all hMDM we examined express DRD5, we wanted to

determine if different levels of DRD5 expression might affect dopamine-induced IL-1 β production. To do this, we split donor DRD5 expression into quartiles and examined the effect of dopamine in each group. While there was a trend toward a significantly increased impact of dopamine on IL-1 β production in the 3rd quartile, no other effect of differing DRD5 expression was discerned (Fig. 1G, Wilcoxon tests, low DRD5, $n=11$, $p=0.1748$, sum of (+, -) ranks 49, - 17; medium DRD5, $n=10$, $p=0.6953$, sum of (+, -) ranks 32, - 23, high DRD5, $n=11$, $p=0.0537$, sum of (+, -) ranks 55, - 1, highest DRD5, $n=10$, $p=0.1309$, sum of (+, -) ranks 43, - 12). Taken together, these data indicate that expression of both D1-like and D2-like receptors can influence IL-1 β production in human macrophages.

The relative expression of D1-like vs. D2-like dopamine receptors (i.e. receptor ratio) shapes excitatory versus inhibitory signaling [140, 141] differentially across brain regions and can change with substances of misuse, influencing drug seeking behavior [207, 213]. Dopamine receptor ratios could therefore be equally important in immune cells and the regulation of inflammatory signaling [180]. Therefore, we further stratified our data to examine how the combination of expression or absence of two dopamine receptors might influence dopamine-mediated increases in IL-1 β (Table 1). The only receptor combination where we detected significant dopamine-mediated increases in IL-1 β production was in samples with detectable DRD3 and DRD4 expression (Wilcoxon tests, DRD3+DRD4+, $n=7$, $*p=0.0156$, sum of (+, -) ranks 28, 0; DRD3 - DRD4+, $n=6$, $p=0.5625$, sum of (+, -) ranks 14, - 7, DRD3+DRD4-, $n=2$, N/A, DRD3 - DRD4 -, $n=27$, $p=0.1482$, sum of (+, -) ranks 250, - 128). These data suggest that the specific combination of dopamine receptors expressed may be just as important as expression of a single receptor when mediating dopamine's effects on IL-1 β .

We also examined whether demographic details including sex, CMV status, and age influenced the observed dopamine-mediated increase in IL-1 β production. Understanding these relationships is important as regulation of sex hormones can impact dopamine synthesis, release, turnover, and degradation [17, 208, 223], CMV virus can alter catecholamine metabolism [33, 177], and dopaminergic dysfunction plays a role in modulating inflammation in the elderly [78, 216]. Interestingly, while hMDM from males showed a significant dopamine-mediated increase in IL-1 β production, the magnitude of the dopamine-induced fold change in IL-1 β was greatest in hMDM from females (Supplementary Fig. 2A, Wilcoxon tests, Male, $n=23$, $*p=0.0354$, sum of (+, -) ranks 207, -69; Female, $n=17$, $p=0.7119$, sum of (+, -) ranks 85, -68). We also examined the distribution

of dopamine receptor subtypes on hMDM from male and female donors. While there were small differences in the expression of the receptors in hMDM from males and females, there was no statistical difference in expression of any of the dopamine receptor subtypes (Supplementary Fig. 2B). We also found that infection with CMV does not significantly impact dopamine-mediated changes in IL-1 β production (Supplementary Fig. 2C, Wilcoxon tests, CMV -, $n=12$, $p=0.3013$, sum of (+, -) ranks 53, - 25; CMV +, $n=15$, $p=0.3591$, sum of (+, -) ranks 77, - 43). This was somewhat surprising, as our prior publication [173] showed that in CMV-infected donors, dopamine increased NF- κ B activity, a precursor to IL-1 β production. However, the dopamine-induced fold change in IL-1 β was greatest in donors who were CMV + (fold change of 2.186 ± 0.8615 SEM (CMV +) vs. fold change of 1.388 ± 0.5214 SEM (CMV -)). Finally, age-related analyses showed a trend in that donors under 50 had a dopamine-mediated increase in IL-1 β production, although the dopamine-induced fold change in IL-1 β was greatest in donors over 50 (Supplementary

Table 1 Different combinations of dopamine receptors expressed on primary macrophages changes dopamine's effects on IL-1 β production

Stratification	N	Dopamine-mediated fold change	p value	SD
DRD1 + DRD2 +	19	2.36	0.087	4.09
DRD1 - DRD2 +	8	1.48	0.188	1.39
DRD1 + DRD2 -	11	1.26	0.278	1.30
DRD1 - DRD2 -	4	1.34	0.625	1.43
DRD1 + DRD3 +	4	1.37	0.125	1.70
DRD1 - DRD3 +	5	1.86	0.313	2.82
DRD1 + DRD3 -	26	1.995	0.075	3.11
DRD1 - DRD3 -	7	1.05	0.938	1.12
DRD1 + DRD4 +	8	2.14	0.055	2.78
DRD1 - DRD4 +	5	1.23	0.438	1.39
DRD1 + DRD4 -	22	1.87	0.166	3.24
DRD1 - DRD4 -	7	1.15	0.938	1.47
DRD2 + DRD3 +	7	1.78	0.156	2.84
DRD2 - DRD3 +	2	1.39	N/A	1.79
DRD2 + DRD3 -	20	1.59	0.294	2.31
DRD2 - DRD3 -	13	1.28	0.244	1.22
DRD2 + DRD4 +	9	1.46	0.055	1.58
DRD2 - DRD4 +	4	1.02	0.875	0.82
DRD2 + DRD4 -	18	1.78	0.640	3.26
DRD2 - DRD4 -	11	1.39	0.169	1.05
DRD3 + DRD4 +	7	1.89	0.016	2.96
DRD3 - DRD4 +	6	1.25	0.563	1.58
DRD3 + DRD4 -	2	0.51	N/A	0.65
DRD3 - DRD4 -	27	1.60	0.148	2.41

Fig. 2D, Wilcoxon tests, Under 50, $n=29$, $p=0.0724$, sum of (+, -) ranks 301, - 134; Over 50, $n=11$, $p=0.5195$, sum of (+, -) ranks 41, - 25). These data suggest that a proportion of the heterogeneity we see with dopamine-mediated changes in IL-1 β may be attributable to demographic factors.

As IL-1 β production can be influenced by ATP and other damage associated molecular patterns associated with cell death, we evaluated the cytotoxicity of the dopamine concentrations used in these studies. A subset of donors was treated with a range of dopamine concentrations for 24 h and assessed using a LIVE/DEAD cell imaging assay ($n=5$) or quantification of LDH release ($n=8$). In both assays, 24 h of vehicle treatment showed a 2–3% decrease in viability. Compared with vehicle treated cells, neither assay showed a significant decrease in viability in response to 10^{-6} M dopamine, as used in our study. However, the two highest concentrations of dopamine used (10^{-4} M and 5×10^{-4} M) did show a slight but significant decrease in cell viability, from 97.927% in vehicle to 92.549% at 10^{-4} M and 86.028% at 5×10^{-4} M. Representative images of the LIVE/DEAD assay are shown (Supplementary Fig. 1A) along with the pooled data (Supplementary Fig. 1B, Friedman test, $n=5$, Friedman statistic 24.37, $**p=0.020$; *Post-hoc* with Dunn's multiple comparisons, vehicle vs. 1×10^{-4} M: $*p=0.0214$, vehicle vs. 5×10^{-4} M $**p=0.0065$). Analysis of cell viability by LDH assay showed similar results, with the highest three concentrations of dopamine reducing viability from 96.15% in vehicle to 89.4% at 10^{-5} M, 86% at 10^{-4} M and 80.5% at 5×10^{-4} M (Supplementary Fig. 1C, Friedman test, $n=8$, Friedman statistic 54.33, $****p<0.0001$; *Post-hoc* with Dunn's multiple comparisons, vehicle vs. 1×10^{-5} M, $***p=0.001$, vehicle vs. 1×10^{-4} M $****p<0.0001$, vehicle vs. 5×10^{-4} M $****p<0.0001$).

IL-1 β and dopamine receptor expression levels in primary human myeloid cells change with maturation

A number of studies have examined dopamine receptor gene and protein expression in myeloid cells [45, 81, 104, 147, 152, 170, 172]. However, it is not clear if the expression is a characteristic of cell type and/or if maturation from monocytes to macrophages could affect receptor levels. To examine this, we evaluated how dopamine receptor expression changed in PBMC, monocytes and hMDM, many of which were derived from the same donor. There was significantly higher D1-like receptor expression in mature hMDM than in PBMC and monocytes (Fig. 2A, Kruskal–Wallis test, $n=33$ –42; **DRD1** Kruskal–Wallis statistic 16.48, $***p=0.0003$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $***p=0.0008$, hMDM vs PBMC, $**p=0.0021$, Monocytes vs PBMC, $p>0.999$; **DRD5**, Kruskal–Wallis

statistic 19.41, $****p<0.0001$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $**p=0.0013$, hMDM vs PBMC, $***p=0.0002$, Monocytes vs PBMC, $p>0.999$). The D2-like receptors were more divergent, with only DRD2 showing significantly higher expression in hMDM compared to PBMC and monocytes (Fig. 2A, Kruskal–Wallis test, $n=33$ –42, Kruskal–Wallis statistic 13.56, $**p=0.0011$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $**p=0.0011$, hMDM vs PBMC, $**p=0.0299$, Monocytes vs PBMC, $p=0.7225$). Expression of DRD3 was significantly higher expression in PBMC than in hMDM and monocytes (Fig. 2A, Kruskal–Wallis test, $n=33$ –42, Kruskal–Wallis statistic 41.21, $****p<0.0001$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $p=0.8594$, hMDM vs PBMC, $****p<0.0001$, Monocytes vs PBMC, $****p<0.0001$). Further, DRD4 expression was significantly lower in hMDM than in both PBMC and monocytes (Fig. 2A, Kruskal–Wallis test, $n=33$ –42, Kruskal–Wallis statistic 77.21, $****p<0.0001$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $****p<0.0001$, hMDM vs PBMC, $****p<0.0001$, Monocytes vs PBMC, $p=0.0712$).

Another way to examine changes in relative receptor expression is to determine the ratio of D1-like to D2-like receptors, by pooling the values for D1-like receptor expression and dividing them by the pooled values for D2-like expression for every donor, as we have done previously [152]. Analysis of D1-like / D2-like ratios found that hMDM have a significantly higher and more variable D1-like to D2-like receptor ratio ($12,169 \pm 37,086$) compared to monocytes (86.36 ± 411.9) or PBMCs (16.62 ± 23.5) (Fig. 2B, Kruskal–Wallis test, $n=33$ –42, Kruskal–Wallis statistic 51.46, $****p<0.0001$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $****p<0.0001$, Monocytes vs PBMC, $p>0.999$, hMDM vs PBMC, $****p<0.0001$). This shows that dopamine receptor expression levels in macrophages are distinct from those in monocytes and PBMCs. Using these data, we then correlated dopamine receptor mRNA expression with IL-1 β mRNA expression in each cell population. Expression of DRD1, DRD2, DRD3, and DRD5 were positively correlated with IL-1 β expression in hMDM (Supplementary Fig. 3A–D, hMDM IL-1 β vs DRD1, $n=28$, Spearman $r=0.4921$, $**p=0.0078$, hMDM IL-1 β vs DRD2, $n=28$, Spearman $r=0.4910$, $*p=0.0265$, hMDM IL-1 β vs DRD3, $n=28$, Spearman $r=0.6134$, $***p=0.0005$, hMDM IL-1 β vs DRD5, $n=28$, Spearman $r=0.4877$, $**p=0.0085$). In monocytes, the only significant correlation was a positive correlation between DRD2 and IL-1 β (Supplementary Fig. 3E, Monocytes IL-1 β vs DRD2, $n=28$, Spearman $r=0.4735$, $*p=0.0109$), and there were no positive correlations in PBMC.

To confirm that the observed correlations were not solely due to differences in baseline IL-1 β , we examined levels of IL-1 β transcript in untreated PBMC, monocytes and hMDM. Monocytes expressed significantly higher IL-1 β mRNA relative to hMDM, but no other differences were observed between the three cell populations (Supplementary Fig. 3F, Kruskal–Wallis test, $n=28-32$, Kruskal–Wallis statistic 9.905, $**p=0.0071$, *Post-hoc* with Dunn's multiple comparisons, Monocytes vs. hMDM, $**p=0.0055$, Monocytes vs PBMC, $p=0.1302$, hMDM vs PBMC, $p=0.7332$). As most of the correlations with dopamine receptor expression were in hMDM, these data indicate that the correlations are not driven by higher baseline IL-1 β . Together, these data show that dopamine receptor expression varies between types of myeloid cells and changes with maturation. These data also suggest the dopamine receptor levels in hMDM, namely the high D1-like to D2-like ratio, may be important in driving the inflammatory effect of dopamine in this cell type.

Dopamine receptor-dependent effects on IL-1 β expression in human microglia

Since we detected differences in dopamine receptor expression between monocytes and MDMs, we speculated that microglia could respond differently from MDMs to dopamine. To answer this question, we used the C06 and C20 human microglial cell lines [4, 77, 189, 228]. These cells express numerous microglial markers, including CD11b, TMEM119, CD68, TGF β R, and P2RY12, maintain migratory capacity and phagocytic activity characteristic of microglia, and expressed P2RY12 and TMEM119 in our culture system (Supplementary Fig. 4).

Both the C06 and C20 cells expressed mRNA for DRD1, DRD2, and DRD5, but not DRD3 or DRD4. Interestingly, the pattern of dopamine receptor expression was dissimilar between the cell lines. The C20 cells have significantly more DRD1 than the C06 cells (Mann–Whitney test, $n=8$, $**p=0.0070$, sum of (C06 D1 vs C20 D1) ranks 43, 93, $U=7$), while the C06 cells have significantly more DRD2 than the C20 cells (Mann–Whitney test, $n=7-9$, $***p=0.0002$, sum of (C06 D2 vs C20 D2) ranks 91, 45, $U=0$). There was no difference in baseline DRD5 expression between the lines (Mann–Whitney test, $n=7-8$, $p=0.6943$, sum of (C06 D5 vs C20 D5) ranks 52, 68, $U=24$). When considering these differences within each line, the C06 cells showed significantly higher DRD2 expression compared to the D1-like receptors, DRD1 and DRD5 (Fig. 3A, Kruskal–Wallis test, $n=7-8$, Kruskal–Wallis statistic 8.666, $**p=0.0082$; *Post-hoc* with Dunn's multiple comparisons, D1 vs. D2, $*p=0.0449$, D5 vs. D2, $*p=0.0224$). Conversely, in C20 cells, there was

significantly higher expression of the D1-like receptors compared to DRD2 (Fig. 3B, Kruskal–Wallis test, $n=8-9$, Kruskal–Wallis statistic 19.07, $***p<0.0001$; *Post-hoc* with Dunn's multiple comparisons, DRD1 vs. DRD2, $***p<0.0001$, DRD5 vs. DRD2, $*p=0.0423$). When calculating the D1-like to D2-like receptor ratio in both cell lines, we determined that the ratio was 0.29 in C06 cells and 7.7 in C20 cells.

We then took advantage of the differential D1-like to D2-like receptor ratios in the two lines to enable a cleaner comparison of the specific impact of dopamine receptor subtypes on dopamine-mediated IL-1 β . The C06 and C20 cells were treated with dopamine (10^{-6} M) or LPS (10 ng/mL, positive control) for 3 h and examined for IL-1 β mRNA expression. In the C06 cells, which have a low D1-like to D2 ratio, dopamine did not increase IL-1 β mRNA (Fig. 3C, Vehicle vs Dopamine, $n=6$, paired t-test, $p=0.2614$, $t=1.266$, $df=5$). However, in the C20 cells, with a high D1-like to D2 ratio, dopamine significantly increased IL-1 β mRNA (Fig. 3D, Vehicle vs Dopamine, $n=6$, Wilcoxon test, $*p=0.0312$, sum of (+, -) ranks 21, 0). LPS significantly increased IL-1 β expression in both cell lines (Fig. 3C, D, C06 IL-1 β Vehicle vs LPS, $n=6$, paired t-test, $@p=0.0114$, $t=3.901$, $df=5$; C20 IL-1 β Vehicle vs LPS, $n=6$, Wilcoxon test, $@p=0.0312$, sum of (+, -) ranks 21, 0), demonstrating that C06 cells still have the capacity to increase IL-1 β mRNA similar to C20 cells.

To verify that the effect of dopamine was impacting IL-1 β production and not only transcription, the C06 and C20 microglia were treated with dopamine (10^{-6} M) for 4 h, then lysates were collected and examined for IL-1 β production. As with mRNA, in the C06 cells (low D1-like to D2 ratio) dopamine treatment did not significantly increase IL-1 β production (Fig. 3E, Vehicle vs Dopamine, $n=6$, Wilcoxon test, $p=0.6875$, sum of (+, -) ranks 8, - 13). However, in the C20 cells (high D1-like to D2 ratio), dopamine did significantly increase IL-1 β production, again in line with the effect on mRNA (Fig. 3F, Vehicle vs Dopamine, $n=6$, paired t-test, $*p=0.0384$, $t=2.790$, $df=5$). In these experiments, Poly I:C treatment was used as a positive control, and it significantly increased expression in both cell lines (Fig. 3E, F, C06 IL-1 β Vehicle vs Poly I:C, $n=6$, Wilcoxon test, $@p=0.0312$, sum of (+, -) ranks 21, 0; C20 IL-1 β Vehicle vs Poly I:C, $n=6$, paired t-test, $@@p=0.0060$, $t=4.564$, $df=5$). Thus, dopamine-mediated increases in IL-1 β production in C20 cells mirrored the change in IL-1 β mRNA levels (increase in C20 IL-1 β Production vs increase C20 IL-1 β mRNA, $n=6$, unpaired t-test with Welch's correction, $p=0.1005$, $t=1.981$, $df=5.361$), indicating that dopamine impacts IL-1 β gene and protein expression similarly in these cells. Therefore mRNA expression was used as a readout in the remainder of these studies.

While dopamine primarily mediates its effects via activation of its cognate receptors, it has also been shown to act on immune cells via adrenergic receptors or through formation of reactive oxygen species [38]. To confirm that the inflammatory effects of dopamine are dependent on dopamine receptor activation, C06 and C20 cells were pretreated with the pan dopamine receptor antagonist flupentixol (Flux, 10^{-6} M) for 30 min followed by 3-h dopamine (DA, 10^{-6} M) treatment. We detected no effect of either dopamine or flupentixol on IL-1 β mRNA expression in C06 microglia (Fig. 3G, rm 2-way ANOVA, Flupentixol, $p=0.4440$ F (1,5)=0.6902, Dopamine, $p=0.3358$ F (1,5)=1.133, Interaction, $p=0.6157$ F (1,5)=0.2860). In contrast, C20 microglia showed a significant, main effect of both flupentixol and dopamine, as well as an interaction between flupentixol and dopamine, in that flupentixol eliminated the dopamine-mediated increase in IL-1 β . (Fig. 3H, rm 2-way mixed effects model and *post-hoc* with Tukey's multiple comparisons, Flupentixol, $**p=0.0013$ F (1,5)=42.08, Dopamine, $*p=0.0203$ F (1,5)=11.23, Interaction, $***p=0.0008$ F (1,4)=81.01, No Flux:Vehicle vs No Flux:Dopamine, $**p=0.0035$, No Flux:Dopamine vs Flux:Vehicle, $**p=0.0031$, No Flux:Dopamine vs Flux:Dopamine, $**p=0.0092$).

To determine how the D1-like to D2-like dopamine receptor ratio mediates regulation of IL-1 β , C20 cells were transduced with a TetR lentivirus followed by a DRD2 lentivirus, creating a cell line in which DRD2 was overexpressed in response to tetracycline (C20D2). To validate the model, the C20D2 cells were exposed to tetracycline and examined for dopamine receptor mRNA expression and compared to wild type (WT) C20 cells. In response to tetracycline, the C20D2 cells expressed significantly more DRD2 than WT C20 microglia (Supplementary Fig. 5A, Kruskal–Wallis test, $n=7-9$, Kruskal–Wallis statistic 18.49, $****p<0.0001$; *Post-hoc* with Dunn's multiple comparisons WT DRD2 vs. C20D2+Tet DRD2, $****p<0.0001$), while also expressing significantly less DRD1 than WT C20 microglia (Supplementary Fig. 5B, one-way ANOVA, $n=7-8$, $***p=0.0005$, F (2, 19)=7.106; *Post-hoc* with Tukey's multiple comparisons, WT DRD1 vs. C20D2+Tet DRD1, $**p=0.0012$). Even in the absence of tetracycline, the C20D2 cells showed significantly less DRD1 (WT DRD1 vs. C20D2 -Tet DRD1, $**p=0.0017$) and trended toward less DRD2 (WT DRD2 vs. C20D2 -Tet DRD2, $p=0.0765$). No significant differences were observed in expression of DRD5 (Supplementary Fig. 5C, one-way ANOVA, $n=7-8$, $p=0.1163$, F (2, 19)=1.380).

As anticipated the overexpression of DRD2 altered the D1-like to D2-like receptor ratio relative to the WT C20 cells. The WT C20 had a ratio of 7.7, while the non-tetracycline exposed C20D2 cells had a ratio of 3.2 and the tetracycline treated C20D2 cells had a ratio of 0.08.

This is very close to that of the WT C06 cells, which had a D1-like to D2-like receptor ratio of 0.29 and indicates a successful shift of the dopamine receptor ratio to resemble the non-dopamine responsive WT C06 cells. Next, we treated the WT C20, the non-tetracycline treated C20D2 and the tetracycline treated C20D2 cells with dopamine (10^{-6} M) for 3 h and examined IL-1 β mRNA. The WT C20 cells (D1-like to D2-like 7.7) showed a twofold increase in IL-1 β , the non-tetracycline treated C20D2 (D1-like to D2-like 3.2) showed a 1.73 fold increase in IL-1 β , and the tetracycline treated C20D2 (D1-like to D2-like 0.08) showed a 1.41 fold increase in IL-1 β . Although the difference was not significant (Supplementary Fig. 7D, one-way ANOVA, $n=6-7$, $p=0.3542$, F (2, 17)=0.6817), the level of response to dopamine directly correlated with the D1-like to D2-like receptor ratio, supporting our hypothesis that the ratio of D1-like receptors to D2-like receptors is important for dopamine's effects on inflammation.

Differential gene expression, pathway analysis and upstream regulators in dopamine-treated human microglia

To identify genes and pathways that are activated in dopamine treated C20 cells, we performed RNA-seq. We used a cutoff value of fold change $>|1.1|$ and FDR <0.05 for inclusion in our analyses and there were a total of 1604 genes that were differentially expressed between the vehicle and dopamine treated C20 cells (Fig. 4A). Of these 776 genes were increased and 828 genes were decreased (Supplementary Table 2). Importantly, these analyses confirmed our mRNA analyses, showing that IL-1 β was increased 2.23-fold in dopamine-treated C20 cells, and identified increases in genes that have previously been found to be upregulated [KYNU (4.76-fold), RASD1 (3.51-fold), and PDE4B (2.33-fold)] by dopamine and dopamine receptor agonists in the human U1 monocytic cell line [14] (Fig. 4B, data expressed as transcripts per million (TPM)). Moreover, these data showed that dopamine impacted numerous regulators of inflammation, dopaminergic signaling, and other processes in this microglial cell line.

Some of the genes associated with the modulation of inflammation include; the cytokines and chemokines IL1RN (21.96 fold), IL11 (4.47-fold), CXCL12 (2.83-fold) and IL15 (2.66-fold); ZDHHC11B (52.17-fold), a positive modulator in NF- κ B signaling [134]; IGF1R (2.59-fold), which can alter microglial polarization via TLR4/NF- κ B pathway [212] and several tumor necrosis factor (TNF) receptors, TNFRSF1B (TNFR2, CD120b, 7.41-fold), TNFRSF8 (CD30, 5.38-fold), and TNFRSF18 (GITR, CD357, 2.52-fold) (Fig. 4C. Examples of the genes associated with the regulation of dopaminergic signaling




Fig. 4 Differential gene expression of dopamine-treated human microglia. **A** Dopamine induced both up-regulated (776) and down-regulated (828) genes (fold change >1.1) and $FDR < 0.05$ in C20 microglia. Violin plots showing the relative expression of genes in the two different conditions (vehicle or dopamine), including **(B)** genes previously found to be upregulated by dopamine in myeloid cells, **(C)** genes associated with modulation of inflammation, **(D)** genes associated with regulation of dopaminergic signaling, **(E)** genes associated with Wnt signaling, and **(F)** genes associated with microglia identity and activation

include; DRD1 itself (− 2.12-fold, which may be down-regulated in response to dopamine-mediated activation, SNAP25 (6.62-fold, which is important for neurotransmitter release and has been previously identified inside microglial processes following synaptic contacts [181]; TPPP (28.02-fold), which regulates plasma membrane presentation of the dopamine transporter and enhances cellular sensitivity to dopamine toxicity; and the transporters SLC7A8 (15.18-fold), an Na⁺-independent transporter of neutral amino acids that transports L-DOPA and SLC16A10 (2.16-fold), which mediates Na-independent transport of tryptophan, tyrosine, phenylalanine, and L-DOPA (Fig. 4D). There were also dopamine-mediated

changes in genes associated with Wnt signaling [WNT1 (12.54-fold), WNT7B (− 3.19-fold), DKK2 (− 2.87-fold), and WNT5B (− 2.85-fold)], which is important for normal dopaminergic functioning as well as inflammation and neurodegeneration during dopaminergic dysfunction [123, 142] (Fig. 4E. Last, a number of genes were altered that are associated with microglia identity and activation [CD101 (2.76-fold, MYO16 (− 7.86-fold, KCNN4 (− 2.80-fold, PDGFB (− 3.04-fold, and OXTR (− 2.82-fold] [21, 69, 110, 202, 229] (Fig. 4F).

To evaluate how these alterations might impact production of IL-1 β and other inflammatory pathways, we mapped the changes in gene expression onto known

patterns in canonical pathways using Ingenuity Pathway Analysis (IPA) (Supplementary Table 3). The pathways with the greatest Z-score that showed an increase in dopamine treated cells relative to vehicle were IL-10 Signaling, Protein Kinase A Signaling, PTEN Signaling, PPAR α /RXR α Activation, Activin Inhibin Signaling Pathway, all of which mediate inflammation and most of which involve IL-1 β . The pathways with the greatest Z-score that showed a decrease in dopamine treated cells relative to vehicle included Neuroinflammation Signaling Pathway, IL-8 Signaling, iNOS Signaling, PI3K/AKT Signaling, HIF1 α Signaling, Role of PKR in Interferon Induction and Antiviral Response, Chemokine Signaling, NF- κ B Activation by Viruses, and IL-1 Signaling.

We also used IPA upstream regulator analysis to identify the potential upstream regulators for these pathways based on expected effects between transcriptional regulators and the targets. This predicts relevant transcriptional regulators by examining how many targets are present in the data and compares the direction of changes in these targets to what is defined the literature. If the direction of changes is mostly consistent with a particular activation state, a prediction is made with two statistical measures: the p-value of overlap and Z-score [118], where a positive Z-score indicates activation and a negative Z-score indicates inhibition. This process identified several regulators which are listed in Supplementary Table 4. These include but are not limited to upstream regulators associated with neuronal activity and neurotransmission [NEUROD1 (Z-score 2.373), norepinephrine (Z-score 2.946), FOS (Z-score - 2.026), FOSB (Z-score - 2.2), and SLC16A2 (Z-score - 2.074)], microglia-enriched transcription factors [SAL4 (Z-score 3.889), RARG (Z-score 2.186) and TEAD4 (Z-score - 2.005)] and inflammatory signaling [CD247 (Z-score 2.236), IL9 (Z-score 2.229), TLR9 (Z-score 2.155), AMPK (Z-score 2.08), FHL2 (Z-score - 2.804), IL3 (Z-score - 2.428), CD40 (Z-score - 2.382), HMGXB4 (Z-score - 2.236), PTPN2 (Z-score - 2.219), CD40LG (Z-score - 2.21), CCL5 (Z-score - 2.179), LTA (TNF β) (Z-score - 2.138), TIMP1 (Z-score - 2.111), and NFKB1 (Z-score - 2.015)]. Some notable effects were the activation of norepinephrine, the microglia-enriched transcription factors RARG and TEAD4 [11] and the inhibition of the negative regulator of Wnt signaling, HMGXB4 [99], as well as of NFKB1 and the negative regulators of NF- κ B and inflammasome activation, FHL2 and PTPN2 [53, 93]. These experiments demonstrated a significant interaction between dopamine and the regulation of human microglial inflammation.

Dopamine-induced IL-1 β exacerbated with HIV

Dopamine mediated increases in IL-1 β would be most relevant in the context of chronic inflammatory disease

with highly comorbid substance use disorders (SUDs). One of the diseases that carries this type of SUD burden is infection with Human Immunodeficiency Virus (HIV), in which comorbid SUD is the among the most common neuropsychiatric comorbidities [46, 102, 167]. Our prior data in human macrophages and microglia also show that exposure to dopamine concentrations evoked by the use of psychostimulants (10^{-6} M) significantly increase HIV viral replication [80, 83, 152, 170] (representative images in Fig. 5A and 6C), and that this is specifically driven by activation of dopamine receptors [83, 170]. Importantly, dopamine can also increase the production of inflammatory cytokines and chemokines in virally suppressed, chronically infected HIV patients [172], demonstrating a strong connection between HIV infection, myeloid inflammation, and dopaminergic dysfunction.

To determine how HIV infection impacts the dopamine-mediated increase in IL-1 β in myeloid cells, hMDM were infected for 7 days with 0.5 ng/mL HIV_{ADA}, treated with dopamine (10^{-6} M) for 3 h and examined for IL-1 β mRNA expression. Treatment with dopamine significantly increased IL-1 β expression in HIV-infected hMDM relative to infected cells treated with vehicle (Fig. 5B, Wilcoxon test, $n=14$, $*p=0.0107$, sum of (+, -) ranks 92, - 13). The magnitude of this effect, an almost 70% increase, was nearly twofold greater than what we have previously observed in uninfected hMDM [173]. Expression of NLRP3 paralleled the trend seen with IL-1 β , with the dopamine-treated, HIV-infected cells showing significantly higher NLRP3 mRNA expression compared to vehicle-treated, HIV-infected cells (Fig. 5C, Wilcoxon test, $n=13$, $**p=0.0061$, sum of (+, -) ranks 83, - 8). As some data indicate that activation of inflammasomes by different HIV proteins can act discretely on IL-1 β and IL-18 secretion [214], we also examined the effects of dopamine on 2 other inflammasomes, NLRC4 and AIM2. Dopamine-treated, HIV-infected cells showed significantly higher NLRC4 mRNA expression (Fig. 5D, Wilcoxon test, $n=13$, $*p=0.0327$, sum of (+, -) ranks 76, -15) and a trend towards higher AIM2 mRNA expression (Fig. 5E, Wilcoxon test, $n=13$, $p=0.0942$, sum of (+, -) ranks 49, 13) compared to vehicle-treated, HIV-infected cells. These results are closely mirrored in the dopamine effects on NLRP3, NLRC4, and AIM2 protein expression in these cells. The dopamine-treated, HIV-infected cells had higher NLRP3, NLRC4, and AIM2 protein expression compared to vehicle-treated, HIV-infected cells, although this only reached significance for NLRP3 (Fig. 5F, NLRP3 paired t-test, $n=7$, $*p=0.0133$, $t=3.471$, $df=6$, Fig. 5G, NLRC4 Wilcoxon test, $n=7$, $p=0.0938$, sum of (+, -) ranks 19, - 2, Fig. 5H, AIM2 paired t-test, $n=7$, $p=0.2143$, $t=1.389$, $df=6$). Representative Western blots are shown in Supplementary Fig. 6.




Fig. 5 Dopamine increases IL-1β and inflammasome expression in HIV-infected primary macrophages. **A** Representative immunofluorescent images at 20X objective (DAPI, blue; Phalloidin, red; p24, green) show human monocyte-derived macrophages (hMDM) infected with 0.5 ng/mL HIV_{ADA} and treated with dopamine (10⁻⁶ M) for 7 days. Higher levels of cell fusion and giant cell formation as well as p24 expression (white arrows) are seen in infected dopamine-treated cultures relative to cultures only infected with HIV. hMDM were also infected with 0.5 ng/mL HIV_{ADA} for 7 days and then treated with dopamine (10⁻⁶ M) for 3 h and examined for (B) IL-1β, (C) NLRP3, (D) NLRC4, and (E) AIM2 expression by qPCR. There was a significant increase in IL-1β, NLRP3, and NLRC4 and a trending increase in AIM2 expression with HIV + Dopamine relative to HIV alone. With these same samples we simultaneously extracted protein and examined (F) NLRP3, (G) NLRC4, and (H) AIM2 expression by Western Blot. There was only a significant increase in NLRP3 expression with HIV + Dopamine relative to HIV alone. Significance was determined by paired t-tests and Wilcoxon tests, *p < 0.05 and **p < 0.01

We then performed similar experiments using C06 and C20 microglia to better define the precise effect of HIV infection in CNS myeloid populations. Both C06 and C20 microglia were infected with 2.5 ng/mL HIV_{ADA} for 48 h, then treated with dopamine (10⁻⁶ M) for 3 h and examined for IL-1β mRNA expression. As in the hMDM, dopamine treatment of HIV-infected C20 cells significantly increased the level of IL-1β compared to HIV infection alone (Fig. 6A, HIV vs HIV + Dopamine,

n = 6, paired t-test, **p = 0.0048, t = 4.811, df = 5). This was also nearly a twofold greater increase relative to the uninfected dopamine-mediated increase seen in C20 cells in Fig. 3. As anticipated based on the data in Fig. 3, dopamine did not show any effect on IL-1β on HIV infected C06 microglia (HIV vs HIV + Dopamine, n = 6, paired t-test, p = 0.1954, t = 1.494, df = 5), so the remainder of these experiments focused only on the C20 microglia. Like hMDM, expression of NLRP3 paralleled




Fig. 6 Dopamine increases IL-1 β and NLRP3 in HIV-infected microglia. C20 microglia were infected with 2.5 ng/mL HIV_{ADA} for 48 h, then treated with dopamine (10^{-6} M) for 3 h and examined for **(A)** IL-1 β and **(B)** NLRP3 mRNA expression by qPCR. For both IL-1 β and NLRP3 there was a significant increase with HIV + Dopamine relative to HIV alone. **C** iMicroglia were infected with 1 ng/mL of HIV_{ADA} for 7 days with or without dopamine (10^{-6} M) and representative immunofluorescent images at 60X objective (DAPI, blue; CellMask, red; p24, green) show higher levels of cell fusion and giant cell formation as well as p24 expression (white arrows) in infected dopamine-treated cultures relative to cultures only infected with HIV. iMicroglia were also infected with 1 ng/mL of HIV_{ADA} for 7 days and then treated with dopamine (10^{-6} M) for either 3 h to examine IL-1 β mRNA expression with qPCR or 4 h to examine IL-1 β production by AlphaLISA. **D** Analysis of IL-1 β mRNA levels show dopamine increases IL-1 β in HIV-infected cells. **E** Analysis of lysate IL-1 β levels by AlphaLISA show there is a trend that dopamine increases IL-1 β in HIV-infected cells. Significance was determined by paired t-tests and Wilcoxon tests, * $p < 0.05$ and ** $p < 0.01$

the trend seen with IL-1 β , with the dopamine-treated, HIV-infected cells showing significantly higher NLRP3 mRNA expression compared to vehicle-treated, HIV-infected cells (Fig. 6B, HIV vs HIV + Dopamine, $n=6$, Wilcoxon test, $*p=0.0312$, sum of (+, -) ranks 21, 0). We also examined other inflammasome associated genes in HIV-infected C20 cells, and while dopamine did slightly increase the amount of CASP1 or PYCARD mRNA in these cells, these effects were not significant (Supplementary Fig. 7C, HIV vs HIV + Dopamine, $n=6$, Wilcoxon test, $p=0.3125$, sum of (+, -) ranks 16, -5; Supplementary Fig. 7D, HIV vs HIV + Dopamine, $n=6$, paired t-test, $p=0.1890$, $t=1.520$, $df=5$). Examining the scaffolding proteins for other types of inflammasomes, we found that there was a significant dopamine-mediated decrease in NLRP1 (Supplementary Fig. 7E, HIV vs HIV + Dopamine, $n=6$, paired t-test, $**p=0.0035$, $t=5.194$, $df=5$), and no significant change in NLRC5 (Supplementary Fig. 7F, HIV vs HIV + Dopamine, $n=6$, paired t-test, $p=0.4395$, $t=0.8394$, $df=5$). There was no detectable expression of AIM2 and NLRC4 mRNA in the C20 microglial cell line.

The effect of dopamine in microglia also impact other IL-1 family cytokines, as HIV-infected C20 cells showed a trend toward dopamine decreasing IL-18 mRNA expression (Supplementary Fig. 7A, HIV vs HIV + Dopamine, $n=6$, paired t-test, $p=0.0861$, $t=2.133$, $df=5$). We also examined IL-1 receptor antagonist (IL1rn), a naturally occurring inhibitor of IL-1 β which has also been shown to be upregulated by HIV [120, 175, 231]. and found a 25-fold increase in this gene (Supplementary Fig. 7B, HIV vs HIV + Dopamine, $n=6$, paired t-test, $***p=0.0003$, $t=8.922$, $df=5$), corroborating the 22-fold increase in IL1rn seen in our RNA-seq data.

To verify these findings in a model that more closely match human microglia, we repeated our experiments using iPSC-derived microglia (iMicroglia). These iMicroglia have very similar gene expression to primary human microglia [195] and express the microglial markers TMEM119, P2RY12, and Iba1 in our culture system (Supplementary Fig. 8). We have previously shown that iMicroglia express the D1-like dopamine receptors, DRD1 and DRD5, but not D2-like receptors, and that dopamine significantly increases HIV infection in these cells [152]. In these experiments, iMicroglia were mock-infected or infected with 1 ng/mL of HIV_{ADA} for 7 days and then treated with vehicle (H₂O) or dopamine (10^{-6} M), treated for either 3 h to examine IL-1 β mRNA expression or 4 h to examine IL-1 β production. Dopamine increased IL-1 β mRNA by 2.65-fold (Fig. 6D, HIV vs HIV + Dopamine, $n=3$, paired t-test, $p=0.3940$, $t=1.077$, $df=2$). Analysis of intracellular IL-1 β production showed dopamine increased IL-1 β in HIV-infected cells by 2.06-fold (Fig. 6E, HIV vs HIV + Dopamine, $n=5$,

paired t-test, $p=0.0785$, $t=2.350$, $df=4$), and found that the increase with dopamine is greater in HIV-infected compared to uninfected cells but is not significant (data not shown, Mock-infected vs HIV-infected dopamine-mediated fold change in IL-1 β , $n=5$, paired t-test, $p=0.3721$, $t=1.004$, $df=4$). These data, and the similarity of these effects across all three myeloid models, indicate that dopamine can enhance IL-1 β expression in HIV-infected human macrophages and microglia, and suggest that increased levels of dopamine due to substance misuse or other therapeutics could exacerbate inflammation associated with neuroHIV.

Discussion

These data demonstrate that increased production of IL-1 β by dopamine depends on the distinct dopamine receptor expression on several types of human myeloid cells. hMDM expressing DRD1 showed a significant, dopamine-mediated increase in IL-1 β that was not present in hMDM without DRD1, suggesting this receptor is necessary for the increase. A similar effect was seen for expression of DRD4. And while dopamine-mediated increases in IL-1 β were seen in hMDM both expressing and not expressing DRD2 and DRD3, cells lacking these receptors had a greater magnitude of dopamine-mediated increases in IL-1 β , suggesting that they might be more associated with mitigating inflammation. A similar effect was observed in human microglial cell lines, which showed that dopamine only increased IL-1 β gene and protein expression in microglia with a high ratio of D1-like receptors relative to DRD2. Antagonizing all dopamine receptors on microglia by pre-treatment with flupentixol (pan-dopamine receptor antagonist) confirmed the specificity of these effects to dopamine receptors. Unlike in hMDM, the microglial cell lines showed these effects without the presence of DRD3 and DRD4, suggesting that DRD2 may be the primary driver of dopamine driven anti-inflammatory effects in these cells. Notably, our results suggest that DRD1, a low-affinity receptor, drives pro-inflammatory activity in hMDM while DRD2, a higher-affinity receptor, drives anti-inflammatory activity. This is supported by studies showing that dopamine preferentially binds to D2-like receptors at low concentrations and D1-like receptors at high concentrations [145, 191]. However, the connection between dopamine receptor expression and IL-1 β activity is likely to be more complicated than this. Dopamine receptor affinity for dopamine does not break down strictly by sub-type, as the affinity of DRD5 is higher than that of DRD1 and DRD2 [79]. Further, in hMDM, DRD4 and DRD3, which both have high affinity for dopamine, had opposing effects on dopamine-mediated changes in

IL-1 β . Some of these differences could also be associated with receptor reserve, as this plays a role in the immune cell response to neurotransmitters including dopamine and has been established in T cells [90, 153, 155].

Some of the differences in dopaminergic immunoregulation may also be due to changes in dopamine receptor ratios with maturation, as we show distinct dopamine receptor ratios in human macrophages, monocytes and PBMCs. Our data indicate that hMDM have a significantly greater D1-like / D2-like dopamine receptor ratio than either monocytes or PBMC, and the correlations between dopamine receptor expression and IL-1 β were strongest in hMDM. This was true despite the finding that monocytes expressed significantly greater baseline IL-1 β mRNA than did hMDM, differing from a prior study showing the greatest cytokine expression in human PBMC [10]. This may reflect the fact that monocytes more rapidly release IL-1 β , as they do not need a second signal for inflammasome activation [169]. Our data on dopamine receptor expression also correlate well with a prior study assessing dopamine receptor mRNA expression in monocytes during maturation [45]. Coley and colleagues showed that the mRNA and protein expression of both DRD1 and DRD5 increase as monocytes mature, while DRD4 mRNA and protein decreased with maturation. These data may indicate that the immune cell dopaminergic profile differs between circulating myeloid cells and tissue myeloid cells. Further, they suggest that the high D1-like / D2-like ratio and effects of dopamine on IL-1 β would be more prominent in tissues where dopamine levels are higher, as compared to the relatively low dopamine levels found in circulation [150, 151]. One tissue in which this is clearly the case is the CNS, where the higher levels of dopamine could impact inflammasome activity and IL-1 β production in microglia and other CNS-associated macrophages. These effects could also be compounded in individuals with substance use disorders, as chronic use of stimulants, opioids, nicotine, and alcohol not only alter dopamine release, but can selectively decrease DRD2 availability in the brain across multiple species [68, 161, 218]. This could bias signaling toward D1-like receptors to increase neuroinflammation and potentially promote inflammation-associated addiction behaviors. Prior studies have shown changes in dopamine receptor expression in peripheral blood cells in individuals with SUD [22, 50, 86]. Whether these changes in peripheral immune cells are related to changes in CNS immune function or the development of SUD remains to be further explored, as this could suggest a better understanding of the immune system's role in the susceptibility to SUD.

To examine these connections in more detail, we performed RNA-sequencing on C20 microglia-like cells. Several genes associated with inflammatory and

neurotransmitter signaling were differentially expressed between vehicle and dopamine-treated cells. Importantly, the effects of dopamine on IL-1 β and associated genes (i.e. IL-1 α) were retained in this dataset. Increases in KYN, RASD1, and PDE4B matched previous data in dopamine-treated myeloid cells [14], and we further found notable increases in cytokines/chemokines, TNF receptors, modulators of NF- κ B signaling, and amino acid transporters, as well as decreases in Wnt signaling and microglial activation markers. Notably, many altered genes were associated with NF- κ B signaling, and an NF- κ B signature has been shown to be one factor differentiating microglia from other tissue-macrophages [15]. This suggests that differences in NF- κ B gene expression could be one reason for functional differences between microglia and macrophages regarding their inflammatory response to dopamine. Evaluation of upstream targets using IPA analysis indicated that many pathways modulated by dopamine involve IL-1 β , including IL-10 Signaling, Protein Kinase A Signaling, and PPAR α /RXR α Activation. We also saw decreases in several inflammatory pathways involving these same targets, including Neuroinflammation Signaling, IL-8 Signaling, iNOS Signaling, PI3K/AKT Signaling, HIF1 α Signaling, Role of PKR in Interferon Induction and Antiviral Response, Chemokine Signaling, NF- κ B Activation by Viruses, and IL-1 Signaling. Mapping these changes in gene expression onto functions revealed indicators of upstream regulators associated with neuronal activity and neurotransmission, microglia-enriched transcription factors and inflammatory signaling. Following up on these targets will be important to better understand mechanisms by which dopaminergic dysregulation could influence inflammatory neuropathologies. This could further guide research to better define which dopaminergic medications would mitigate excess inflammation, while sustaining protective inflammatory responses. The contrasting effects of dopamine on pro- and anti-inflammatory responses indicate that modulation of dopaminergic activity could both initiate and inhibit inflammatory cascades. Small changes in dopamine concentrations may shift activity in either direction, depending on the receptor expression on the cell type exposed to dopamine, converting a protective effect into something pathologic. The specific, and often opposing, myeloid signatures identified in the hyper-dopaminergic environment modeled here suggest that increased exposure to dopamine could modulate IL-1 β -mediated inflammatory signaling in human myeloid cells, suggesting an explanation for the variability in inflammatory outcomes in the context of substance use and dopaminergic medication regimens [65, 113, 183].

An example of a neuroinflammatory disease in which there is often dopaminergic dysregulation is HIV. The

prevalence of substance use disorders in people living with HIV is very high [54, 98, 205] and HIV infection itself has been shown to dysregulate the dopaminergic system [12, 19, 122, 127, 137, 200, 221]. These data show that the effects of dopamine on IL-1 β persist and may be exacerbated in the presence of HIV infection in hMDM, C20 microglia, and iPSC-derived microglia. Notably, HIV infection did not increase IL-1 β production relative to uninfected cells, instead mostly producing non-significant decreases in baseline IL-1 β levels (not shown). This comports with prior observations regarding cytokine production in hMDM from ART-treated, HIV-infected individuals [30, 158, 172, 194], although contrasting reports indicate that HIV infection increases macrophage inflammation [70, 73, 91, 185]. These differences could be due the timing of the immune stimulus—in this case HIV infection—as this is very important for IL-1 β production in myeloid cells [197]. For example, peak IL-1 β production in another study using HIV-infected, iPSC-derived human microglia occurred at 16 days post infection [26], while in primary human microglia, HIV infection increased IL-1 β release within 24 h post-infection, which preceded peak production and release of virus (7–10 days post-infection) [220]. Notably, these studies did not use anti-retroviral drugs despite the prevalence of anti-retroviral therapy (ART) in the HIV-infected population. The impact of ART on pro-inflammatory cytokine production, such as IL-1 β , is not well defined [119, 148, 178, 225], although our prior data indicate that ART does not block the effects of dopamine on inflammation [172], and the literature suggests that ART does not return inflammation to baseline levels [75, 188, 203]. Future studies will need to better define the impact of ART on dopaminergic inflammation in HIV-infected individuals.

Beyond the effects on IL-1 β , the interactive effects of dopamine and HIV on inflammasome activity were also examined in hMDM and C20 microglia. In both HIV-infected macrophages and C20 microglia, dopamine significantly increased gene and/or protein expression of NLRP3, correlating well with our data in uninfected myeloid cells in this and our previous studies, as well as other reports showing HIV-infection is associated with elevated NLRP3 activity [13, 41, 70, 173]. However, dopamine had different effects on other inflammasomes in these two cell types, increasing NLRC4 and AIM2 in macrophages, and decreasing NLRP1, with no effect on other inflammasomes, in C20 cells. The different effects of dopamine on discrete types of inflammasomes could be due to the fact that dopamine may not act as the same type of stimuli for all inflammasomes, as certain stimuli are required to activate each inflammasome [234]. Some of these differences could also be cell type-specific, as there are differences in inflammasome expression and

inflammasome-induced IL-1 β secretion among myeloid cells. For example, while caspase 1, 4, and 5 activation is pivotal for inflammasome-induced IL-1 β secretion by hematopoietic macrophages, microglial secretion of IL-1 β is only partially dependent on these inflammatory caspases [34].

There are also multiple types of inflammasomes that can influence production of other IL-1 cytokines, such as IL-18. Surprisingly, in our HIV-infected C20 microglia, the effects of dopamine on IL-18 were dissimilar to IL-1 β in that there was a trend towards a decrease in IL-18 expression. Part of this may be because IL-18 has been shown to be constitutively expressed in myeloid cells [3, 58]. In contrast, IL-1 β is not constitutively expressed under homeostasis and requires induction with TLR ligands or other stimuli. Additionally, IL-18 is considered an inflammasome-regulated cytokine but reports have shown it is only marginally influenced by LPS and ATP at both mRNA and secreted protein levels, suggesting that its modulation is not similar to IL-1 β , and additional pathways may regulate its levels [10]. Indeed, there are several reports for the role of NLRP1 in IL-18 induction [159, 176], which may explain their decreased expression. Further, although inflammasome signaling in the CNS is mainly attributed to microglia, expression of inflammasome components has also been reported in other cell types of the CNS, including perivascular CNS macrophages and astrocytes [111], so important additional cell type-specific differences in inflammasome-mediated responses could contribute to disease pathology [217].

While these data highlight the value in a better understanding of dopaminergic immunomodulation, there are caveats that must be considered when moving this research forward. First, these studies focused on dopamine receptor-mediated effects, but other dopaminergic proteins, such as the dopamine transporter and tyrosine hydroxylase, can also regulate myeloid inflammation [137] and alter the peripheral immune profile in dopaminergic diseases such as Parkinson's disease [88]. Additional limitations for future studies are the limited number of human myeloid cell lines, the lack of access to primary human tissue macrophages—such as microglia—and the well-known variability in primary human monocyte derived macrophages [25, 108]). To address the heterogeneity in the human population, we used hMDM from many donors ($n=42$) relative to many in vitro studies, but the number was still small compared to epidemiological studies examining trends across a human population. For example, for the dopamine receptor combination analyses in Table 1, there were several trends that might have shown significance if the experiments were powered to assess these questions. It is also important to note that the PBMC / monocyte / hMDM

populations described in Fig. 2 and Supplementary Fig. 3 were not matched for every donor, as matched samples were not always available. However, analysis of only the matched PBMC / monocyte / hMDM donor sets ($n=18-19$) showed the same effects, strengthening confidence in these data and strongly indicating that dopamine receptor expression, at least in human myeloid cells, varies with cell type and maturation.

Because acquisition of primary human microglia is logistically difficult, established C06 and C20 immortalized human microglial cells [4, 77, 189, 228] were used for many experiments. These cells showed a clear, replicable dopamine response, but they also show limitations, as they replicate rapidly and do not recapitulate the viral dynamics in primary myeloid cells. Further, we were only able to detect IL-1 β transcripts and intracellular IL-1 β production, not IL-1 β secretion, in these cells. We also could not detect caspase-1, so it is possible other caspases were involved in this response. To address these concerns, studies were performed across three distinct human myeloid model systems, all of which showed the same effects of dopamine. Much of the research on dopaminergic immunology has been performed in rodent models, making the use of multiple human myeloid models one of the major strengths in this study. Further studies in human systems, as well as correlation of the extant rodent research with human data is critical to address issues of translatability arising from species-specific differences in rodent and human immune responses and inflammasome activity [5, 62, 157, 199, 204], which may, in part, contribute to the difficulty translating therapeutics from preclinical models [47, 89, 126]. Similar issues could be caused by differences in dopamine receptor ratios, which also differ across species [140], as well cell-type specific differences in dopamine signaling activity [170]. There could also be differences in desensitization of the dopamine receptors, which are regulatory mechanisms that contribute to the responsiveness to dopamine and dopaminergic drugs [76, 92]. The role of desensitization in immune cell dopamine receptors is unknown but an important area of future investigation. Adding further complexity is the fact that higher concentrations of dopamine can also activate α - and β -adrenergic receptors [128, 182, 196]. These receptors are also expressed in human and rodent immune cells, with relative ratios of adrenergic receptors to dopamine receptors that differ across, species, cell type and brain region [8, 85, 196]. As the data presented here suggest that IL-1 β regulation may relate to differential expression and regulation of dopamine receptors, it is critical to consider these factors to define the inflammatory impact of dopamine more comprehensively.

The inflammatory impact of dopamine could influence a wide array of pathological conditions as it dysregulates inflammation in myeloid cells across regions. Many peripheral tissues with high levels of dopamine harbor one or more types of hMDM populations [146], and it is not clear how the effects of dopamine differ within these populations. However, these data show that there can be substantial differences between myeloid cell types. Thus, our ongoing research is interrogating the effects of dopamine on inflammasome activity and immune responses in tissue-specific myeloid cell types. Many of these effects could be exacerbated in the presence of diseases, substances of misuse and therapeutics that dysregulate the dopaminergic system [82]. For example, a number of neuropsychiatric diseases associated with altered dopaminergic neurotransmission are also associated with inflammation, and a number of neurotransmitter-altering therapeutics used to treat these diseases also impact inflammation [35, 38, 95, 103, 112, 121, 149–151, 166, 224]. It is possible that the changes in the dopaminergic system resulting from either the disease or the treatment could create a vicious cycle, altering myeloid activity to exacerbate disease, reducing or counteracting the effectiveness of treatment, and promoting further dysregulation that drives the cycle forward. A similar effect could be produced in neuroHIV, where the aging, HIV-infected population is frequently prescribed dopamine-modulating therapeutics for age-associated comorbidities, such as Alzheimer's, Parkinson's, diabetes, and some cancers [150, 151].

With a better understanding of the inflammatory processes driven by dopamine, such as the interaction between dopamine receptor-mediated signaling and IL-1 β , a combination of targeting IL-1 β alongside dopaminergic machinery could be a promising avenue to prevent or limit widespread chronic immune activation associated with numerous pathologies. Overall, these data demonstrate the remarkable complexity of dopaminergic immunomodulation and indicate that more research is needed to better understand how these effects are regulated, how they differ throughout the body, and how best to use this knowledge to repurpose or develop new medication regimens in the context of HIV and other brain diseases associated with chronic inflammation.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12974-025-03403-9>.

Additional file 1.

Additional file 2.

Additional file 3.

Additional file 4.

Acknowledgements

We would like to state our tremendous appreciation for all the individuals who donated the biological materials used in these studies. We would also like to thank all the members of the Gaskill lab as well as Dr. Vasiliki Pappa, Katelyn Reeb, and John Montilla for their contributions to this work.

Author contributions

SMM, RN, and PJG contributed to the design and conception of the study. SMM, RN, BL, MN, JS, HF, and PJG designed and analyzed the experiments, and SMM, RN, SM, YA, BC, OT, MD, JC, TL, KM, KR, ENB, BL, and JS performed the experiments. SMM and PJG helped supervise the project. SMM and PJG performed the statistical analyses and wrote the manuscript. All authors contributed to manuscript revision, read, and approved the final submitted version, and PJG was responsible for the final approval of the submitted version.

Funding

This work was supported by Grants from the National Institutes of Health, DA039005, DA057337, DA058051 and DA049227 (PJG), MH132466 (SMM), T32-MH079785 (supporting RAN, EAN, BC), and F30AI179472 (BC) as well as the W.W. Smith Charitable Trust Foundation Grant A2003 (PJG), the Brody Family Medical Trust Fund (SMM), the Cotswold Foundation Fellowship (SMM), and the Department of Pharmacology and Physiology at Drexel University College of Medicine.

Availability of data and materials

The RNA-seq datasets in the current study have been deposited in GEO (accession # GSE273395).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N. 15th Street, Philadelphia, PA 19102, USA. ²Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA. ³Graduate School of Biomedical Sciences and Professional Studies, Drexel University College of Medicine, Philadelphia, PA 19102, USA. ⁴Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. ⁵Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA. ⁶Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. ⁷Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.

Received: 23 July 2024 Accepted: 1 March 2025

Published: 23 March 2025

References

- Abreu P, Llorente E, Hernández MM, González MC. Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence. *NeuroReport*. 1994;5(11):1356–8.
- Agrawal I, Sharma N, Saxena S, Arvind S, Chakraborty D, Chakraborty DB, et al. Dopamine induces functional extracellular traps in microglia. *iScience*. 2021;24(1):101968.
- Ahmad R, Sindhu ST, Toma E, Morisset R, Ahmad A. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. *J Virol*. 2002;76(24):12448–56.
- Alvarez-Carbonell D, Ye F, Ramanath N, Garcia-Mesa Y, Knapp PE, Hauser KF, et al. Cross-talk between microglia and neurons regulates HIV latency. *PLoS Pathog*. 2019;15(12): e1008249.
- Ariffin JK, Sweet MJ. Differences in the repertoire, regulation and function of Toll-like Receptors and inflammasome-forming Nod-like Receptors between human and mouse. *Curr Opin Microbiol*. 2013;16(3):303–10.
- Armando I, Villar VA, Jose PA. Dopamine and renal function and blood pressure regulation. *Compr Physiol*. 2011;1(3):1075–117.
- Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. *JAMA Psychiat*. 2017;74(5):511–9.
- Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, et al. Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. *Transl Psychiatry*. 2021;11(1):59.
- Avalos CR, Price SL, Forsyth ER, Pin JN, Shirk EN, Bullock BT, et al. Quantitation of productively infected monocytes and macrophages of simian immunodeficiency virus-infected macaques. *J Virol*. 2016;90(12):5643–56.
- Awad F, Assrawi E, Jumeau C, Georgin-Lavialle S, Cobret L, Duquesnoy P, et al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation. *PLoS ONE*. 2017;12(4): e0175336.
- Ayata P, Badimon A, Strasburger HJ, Duff MK, Montgomery SE, Loh YE, et al. Epigenetic regulation of brain region-specific microglia clearance activity. *Nat Neurosci*. 2018;21(8):1049–60.
- Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. *Neurology*. 1993;43(10):2099–104.
- Bandera A, Masetti M, Fabbiani M, Biasin M, Muscatello A, Squillace N, et al. The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery. *Front Immunol*. 2018;9:214.
- Basova LV, Lindsey A, McGovern A, Rosander A, Delorme-Walker V, ElShamy WM, et al. MRP8/14 is a molecular signature triggered by dopamine in HIV latent myeloid targets that increases HIV transcription and distinguishes HIV+ methamphetamine users with detectable CSF viral load and brain pathology. *Viruses*. 2023. <https://doi.org/10.3390/v15061363>.
- Batista SJ, Still KM, Johanson D, Thompson JA, O'Brien CA, Lukens JR, et al. Gasdermin-D-dependent IL-1 α release from microglia promotes protective immunity during chronic *Toxoplasma gondii* infection. *Nat Commun*. 2020;11(1):3687.
- Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol Rev*. 2011;63(1):182–217.
- Becker JB. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. *Neurosci Lett*. 1990;118(2):169–71.
- Becker JT, Sanders J, Madsen SK, Ragin A, Kingsley L, Maruca V, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. *Brain Imaging Behav*. 2011;5(2):77–85.
- Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B. Cerebrospinal fluid dopamine in HIV-1 infection. *AIDS*. 1994;8(1):67–72.
- Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. *J Neurochem*. 1999;73(3):1127–37.
- Bi Q, Wang C, Cheng G, Chen N, Wei B, Liu X, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. *Immunity*. 2022;55(8):1466–1482.e1469.
- Biermann T, Bonsch D, Reulbach U, Kornhuber J, Bleich S. Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal. *J Neural Transm (Vienna)*. 2007;114(8):1081–4.
- Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of $\Delta(9)$ -tetrahydrocannabinol on the dopamine system. *Nature*. 2016;539(7629):369–77.

24. Blum K, Thanos PK, Gold MS. Dopamine and glucose, obesity, and reward deficiency syndrome. *Front Psychol.* 2014;5:919.
25. Bol SM, van Remmerden Y, Sietzema JG, Kootstra NA, Schuitemaker H, van't Wout AB. Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. *Virology.* 2009;390(2):205–11.
26. Boreland AJ, Stillitano AC, Lin HC, Abbo Y, Hart RP, Jiang P, et al. Sustained type I interferon signaling after human immunodeficiency virus type 1 infection of human iPSC derived microglia and cerebral organoids. *iScience.* 2024;27(5):109628.
27. Borrajo A, Spuch C, Penedo MA, Olivares JM, Agís-Balboa RC. Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. *Ann Med.* 2021;53(1):43–69.
28. Borrajo López A, Penedo MA, Rivera-Baltanas T, Pérez-Rodríguez D, Alonso-Crespo D, Fernández-Pereira C, et al. Microglia: the real Foe in HIV-1 associated neurocognitive disorders? *Biomedicines.* 2021;9(8):925.
29. Brannan T, Martinez-Tica J, Di Rocco A, Yahr MD. Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study. *J Neural Transm Park Dis Dement Sect.* 1993;6(2):81–7.
30. Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM. HIV-1 activates macrophages independent of toll-like receptors. *PLoS ONE.* 2008;3(12): e3664.
31. Brown KT, Levis SC, O'Neill CE, Northcutt AL, Fabisak TJ, Watkins LR, et al. Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking. *Brain Behav Immun.* 2018;67:130–8.
32. Brown SW, Meyers RT, Brennan KM, Rumble JM, Narasimhachari N, Perozzi EF, et al. Catecholamines in a macrophage cell line. *J Neuroimmunol.* 2003;135(1–2):47–55.
33. Burgdorf KS, Trabjerg BB, Pedersen MG, Nissen J, Banasik K, Pedersen OB, et al. Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. *Brain Behav Immun.* 2019;79:152–8.
34. Burm SM, Zuiderwijk-Sick EA, Jong AET, van der Putten C, Veth J, Kondova I, et al. Inflammasome-induced IL-1 β secretion in microglia is characterized by delayed kinetics and is only partially dependent on inflammatory caspases. *J Neurosci.* 2015;35(2):678–87.
35. Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE. The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. *Curr Neuropharmacol.* 2011;9(2):278–88.
36. Cearley CN, Blindheim K, Sorg BA, Krueger JM, Churchill L. Acute cocaine increases interleukin-1 β mRNA and immunoreactive cells in the cortex and nucleus accumbens. *Neurochem Res.* 2011;36(4):686–92.
37. Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. *J Exp Med.* 2020;217(1):e20190314.
38. Channer B, Matt SM, Nickoloff-Bybel EA, Pappa V, Agarwal Y, Wickman J, et al. Dopamine, immunity and disease. *Pharmacol Rev.* 2022;75:62–158.
39. Cheung R, Ravyn V, Wang L, Ptasznik A, Collman RG. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1 β release in primary human macrophages. *J Immunol.* 2008;180(10):6675–84.
40. Chilunda V, Calderon TM, Martinez-Aguado P, Berman JW. The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era. *Brain Res.* 2019;1724: 146426.
41. Chivero ET, Guo ML, Periyasamy P, Liao K, Callen SE, Buch S. HIV-1 tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation. *J Neurosci.* 2017;37(13):3599–609.
42. Cincotta AH, Cersosimo E, Alatrach M, Ezrokhi M, Agyin C, Adams J, et al. Bromocriptine-QR therapy reduces sympathetic tone and ameliorates a pro-oxidative/pro-inflammatory phenotype in peripheral blood mononuclear cells and plasma of type 2 diabetes subjects. *Int J Mol Sci.* 2022;23(16):8851.
43. Clayton KL, Garcia JV, Clements JE, Walker BD. HIV infection of macrophages: implications for pathogenesis and cure. *Pathog Immun.* 2017;2(2):179–92.
44. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, et al. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. *J Immunol.* 1991;147(9):2892–901.
45. Coley JS, Calderon TM, Gaskill PJ, Eugenin EA, Berman JW. Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. *PLoS ONE.* 2015;10(2): e0117450.
46. Cook JA, Burke-Miller JK, Steigman PJ, Schwartz RM, Hessel NA, Milam J, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multi-site cohort of women living with HIV. *AIDS Behav.* 2018;22(10):3141–54.
47. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans. *Clin Diagn Lab Immunol.* 2005;12(1):60–7.
48. Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME. Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. *J Neurophysiol.* 2001;85(4):1761–71.
49. Cui C, Shurtleff D, Harris RA. Neuroimmune mechanisms of alcohol and drug addiction. *Int Rev Neurobiol.* 2014;118:1–12.
50. Czemak C, Lehofer M, Wagner EM, Prietl B, Lemonis L, Rohrerhofer A, et al. Reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent alcohol and heroin addicts. *Addiction.* 2004;99(2):251–7.
51. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Muller JG, et al. Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. *Acta Neuropathol.* 2004;107(3):216–26.
52. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, et al. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. *Acta Neuropathol.* 2001;101(2):85–91.
53. Dahan J, Levillayer F, Xia T, Nouët Y, Werts C, Fanton d'Andon M, et al. "LIM-Only Protein FHL2 is a negative regulator of transforming growth factor β 1 expression. *Mol Cell Biol.* 2017;37(10).
54. Deren S, Cortes T, Dickson VV, Guilamo-Ramos V, Han BH, Karpiak S, et al. Substance use among older people living with HIV: challenges for health care providers. *Front Public Health.* 2019;7:94.
55. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. *Eur J Pharmacol.* 1999;375(1–3):13–30.
56. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur J Pharmacol.* 2000;393(1–3):295–314.
57. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. *Nat Biotechnol.* 2017;35(4):316–9.
58. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. *Front Immunol.* 2013;4:289.
59. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15–21.
60. Dominguez-Mejide A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. *Brain Behav Immun.* 2017;62:277–90.
61. Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. *Behav Med.* 2014;40(2):43–52.
62. Egan MS, Zhang J, Shin S. Human and mouse NAIP/NLRC4 inflammasome responses to bacterial infection. *Curr Opin Microbiol.* 2023;73: 102298.
63. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, et al. Substantial production of dopamine in the human gastrointestinal tract. *J Clin Endocrinol Metab.* 1997;82(11):3864–71.
64. Emanuel KM, Runner K, Brodnik ZD, Morsey BM, Lamberty BG, Johnson HS, et al. Deprenyl reduces inflammation during acute SIV infection. *iScience.* 2022;25(5):104207.
65. Ermakov EA, Melamed MM, Boiko AS, Kamaeva DA, Ivanova SA, Nevinsky GA, et al. Association of peripheral inflammatory biomarkers and growth factors levels with sex, therapy and other clinical factors in schizophrenia and patient stratification based on these data. *Brain Sci.* 2023;13(5):836.
66. Fan Y, Chen Z, Pathak JL, Carneiro AMD, Chung CY. Differential regulation of adhesion and phagocytosis of resting and activated microglia by dopamine. *Front Cell Neurosci.* 2018;12:309–309.
67. Farhadian SF, Lindenbaum O, Zhao J, Corley MJ, Im Y, Walsh H, et al. HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART. *JCI Insight.* 2022;7(13):e160267.

68. Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. *Am J Psychiatry*. 2008;165(4):507–14.
69. Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. *Nat Commun*. 2019;10(1):409.
70. Feria MG, Taborda NA, Hernandez JC, Rugeles MT. HIV replication is associated to inflammasomes activation, IL-1 β , IL-18 and caspase-1 expression in GALT and peripheral blood. *PLoS ONE*. 2018;13(4):e0192845–e0192845.
71. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. *J Psychopharmacol*. 2008;22(2 Suppl):12–9.
72. Flierl MA, Rittirsch D, Nadeau BA, Sarma JV, Day DE, Lentsch AB, et al. Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. *PLoS ONE*. 2009;4(2): e4414.
73. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. *Science*. 1987;238(4828):800–2.
74. Frank MG, Adhikary S, Sobesky JL, Weber MD, Watkins LR, Maier SF. The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine. *Brain Behav Immun*. 2016;51:99–108.
75. Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. *Curr Opin HIV AIDS*. 2014;9(1):80–6.
76. Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. *Neuron*. 2003;38(2):291–303.
77. Garcia-Mesa Y, Jay TR, Checkley MA, Luttge B, Dobrowolski C, Valadkhan S, et al. Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system. *J Neurovirol*. 2017;23(1):47–66.
78. Garrido-Gil P, Dominguez-Mejide A, Moratalla R, Guerra MJ, Labandeira-Garcia JL. Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly. *Oncotarget*. 2018;9(13):10834–46.
79. Gaskill PJ, Calderon TM, Coley JS, Berman JW. Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. *J Neuroimmune Pharmacol*. 2013;8(3):621–42.
80. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. *Am J Pathol*. 2009;175(3):1148–59.
81. Gaskill PJ, Carvallo L, Eugenin EA, Berman JW. Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. *J Neuroinflammation*. 2012;9:203.
82. Gaskill PJ, Khoshbouei H. Dopamine and norepinephrine are embracing their immune side and so should we. *Curr Opin Neurobiol*. 2022;77: 102626.
83. Gaskill PJ, Yano HH, Kalpana GV, Javitch JA, Berman JW. Dopamine receptor activation increases HIV entry into primary human macrophages. *PLoS ONE*. 2014;9(9): e108232.
84. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. *J Exp Med*. 1988;167(4):1428–41.
85. Goldman-Rakic PS, Lidow MS, Smiley JF, Williams MS. The anatomy of dopamine in monkey and human prefrontal cortex. *J Neural Transm Suppl*. 1992;36:163–77.
86. Goodarzi A, Vosooghi N, Sedaghati M, Mokri A, Zarrindast MR. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. *Eur J Pharmacol*. 2009;615(1–3):218–22.
87. Gopinath A, Badov M, Francis M, Shaw G, Collins A, Miller DR, et al. TNF α increases tyrosine hydroxylase expression in human monocytes. *NPJ Parkinsons Dis*. 2021;7(1):62.
88. Gopinath A, Mackie P, Hashimi B, Buchanan AM, Smith AR, Bouchard R, et al. DAT and TH expression marks human Parkinson's disease in peripheral immune cells. *NPJ Parkinsons Dis*. 2022;8(1):72.
89. Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzky JCM, Sajti E, et al. An environment-dependent transcriptional network specifies human microglia identity. *Science*. 2017;356:eaal3222.
90. Guieu R, Brignole M, Deharo JC, Deharo P, Mottola G, Groppelli A, et al. Adenosine receptor reserve and long-term potentiation: unconventional adaptive mechanisms in cardiovascular diseases? *Int J Mol Sci*. 2021;22(14):7584.
91. Guo H, Gao J, Taxman DJ, Ting JPY, Su L. HIV-1 infection induces interleukin-1 β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. *J Biol Chem*. 2014;289(31):21716–26.
92. Gurevich EV, Gainetdinov RR, Gurevich VV. G protein-coupled receptor kinases as regulators of dopamine receptor functions. *Pharmacol Res*. 2016;111:1–16.
93. Ha Thi HT, Choi SW, Kim YM, Kim HY, Hong S. Protein tyrosine phosphatase N2 is a positive regulator of lipopolysaccharide signaling in Raw264.7 cell through derepression of Src tyrosine kinase. *PLoS ONE*. 2016;11(9): e0162724.
94. Han X, Ni J, Wu Z, Wu J, Li B, Ye X, et al. Myeloid-specific dopamine D2 receptor signalling controls inflammation in acute pancreatitis via inhibiting M1 macrophage. *Br J Pharmacol*. 2020;177(13):2991–3008.
95. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. *Neuropsychopharmacology*. 2011;36(12):2452–9.
96. Harris RC, Zhang M-Z. Dopamine, the kidney, and hypertension. *Curr Hypertens Rep*. 2012;14(2):138–43.
97. Harshil Patel, P. E., Alexander Peltzer, Olga Botvinnik, Jonathan Manning, Gregor Sturm, Maxime U Garcia, Denis Moreno, Pranathi Vemuri, nf-core bot, silviamorins, Lorena Pantano, Mahesh Binzer-Panchal, Matthias Zepper, Robert Syme, Gavin Kelly, Friederike Hanssen, Adam Talbot, James A. Fellows Yates, ... Paolo Di Tommaso. (2023). nf-core/rnaseq: nf-core/rnaseq v3.13.2 - Cobalt Colt (3.13.2). Zenodo.
98. Hartzer B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS Behav*. 2017;21(4):1138–48.
99. He X, Dong K, Shen J, Hu G, Liu J, Kang X, et al. Deficiency of the novel high mobility group protein HMGB4 protects against systemic inflammation-induced endotoxemia in mice. *Proc Natl Acad Sci U S A*. 2021;118(7):e2021862118.
100. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell*. 2010;38(4):576–89.
101. Herz J, Filiano AJ, Wiltbank AT, Yogev N, Kipnis J. Myeloid cells in the central nervous system. *Immunity*. 2017;46(6):943–56.
102. Heslin M, Jewell A, Croxford S, Chau C, Smith S, Pittrof R, et al. Prevalence of HIV in mental health service users: a retrospective cohort study. *BMJ Open*. 2023;13(4): e067337.
103. Hiles SA, Baker AL, de Malmanche T, Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. *Psychol Med*. 2012;42(10):2015–26.
104. Huck JHJ, Freyer D, Böttcher C, Mladinov M, Muselmann-Genschow C, Thielke M, et al. De novo expression of dopamine D2 receptors on microglia after stroke. *J Cereb Blood Flow Metab*. 2015;35(11):1804–11.
105. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. *Eur J Pharmacol*. 1995;281(3):255–61.
106. Ipser JC, Brown GG, Bischoff-Grethe A, Connolly CG, Ellis RJ, Heaton RK, et al. HIV infection is associated with attenuated frontostriatal intrinsic connectivity: a preliminary study. *J Int Neuropsychol Soc*. 2015;21(3):203–13.
107. Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: novel T cell biomarker for antidepressant medication selection. *Brain Behav Immun*. 2017;66:103–10.
108. Jobe O, Kim J, Tycksen E, Onkar S, Michael NL, Alving CR, et al. Human primary macrophages derived in vitro from circulating monocytes comprise adherent and non-adherent subsets with differential expression of Siglec-1 and CD4 and permissiveness to HIV-1 infection. *Front Immunol*. 2017;8:1352.

109. Kallianpur KJ, Jahanshad N, Sailasuta N, Benjapornpong K, Chan P, Pothirisri M, et al. Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. *AIDS*. 2020;34(3):415–26.
110. Kaushal V, Koeberle PD, Wang Y, Schlichter LC. The Ca²⁺-activated K⁺ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. *J Neurosci*. 2007;27(1):234–44.
111. Kawana N, Yamamoto Y, Ishida T, Saito Y, Konno H, Arima K, et al. Reactive astrocytes and perivascular macrophages express NLRP3 inflammasome in active demyelinating lesions of multiple sclerosis and necrotic lesions of neuromyelitis optica and cerebral infarction. *Clin Exp Neuroimmunol*. 2013;4(3):296–304.
112. Kohler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. *Mol Neurobiol*. 2018;55(5):4195–206.
113. Kohno M, Link J, Dennis LE, McCready H, Huckans M, Hoffman WF, et al. Neuroinflammation in addiction: a review of neuroimaging studies and potential immunotherapies. *Pharmacol Biochem Behav*. 2019;179:34–42.
114. Koka P, He K, Zack JA, Kitchen S, Peacock W, Fried I, et al. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. *J Exp Med*. 1995;182(4):941–51.
115. Kokkinou I, Fragoulis EG, Vassiliacopoulou D. The U937 macrophage cell line expresses enzymatically active L-Dopa decarboxylase. *J Neuroimmunol*. 2009;216(1–2):51–8.
116. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. *Mol Psychiatry*. 2018;23(1):59–69.
117. Kopeck AM, Smith CJ, Ayre NR, Sweat SC, Bilbo SD. Microglial elimination of dopamine D1 receptors defines sex-specific changes in nucleus accumbens development and social play behavior during adolescence. *bioRxiv*. 2017.
118. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523–30.
119. Krebs SJ, Slike BM, Sithinamsuwan P, Allen IE, Chalermchai T, Tipsuk S, et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. *AIDS*. 2016;30(10):1533–42.
120. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. *Clin Exp Immunol*. 1997;109(1):54–8.
121. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, et al. Stimulatory effect of antidepressants on the production of IL-6. *Int Immunopharmacol*. 2004;4(2):185–92.
122. Kumar AM, Fernandez JB, Singer EJ, Commings D, Waldrop-Valverde D, Ownby RL, et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. *J Neurovirol*. 2009;15(3):257–74.
123. L'Episcopo F, Tirolo C, Serapide MF, Caniglia S, Testa N, Leggio L, et al. Microglia polarization, gene-environment interactions and Wnt/ β -catenin signaling: emerging roles of glia-neuron and glia-stem/neuroprogenitor crosstalk for dopaminergic neurorestoration in aged Parkinsonian brain. *Front Aging Neurosci*. 2018;10:12.
124. Lacagnina MJ, Rivera PD, Bilbo SD. Glial and neuroimmune mechanisms as critical modulators of drug use and abuse. *Neuropsychopharmacology*. 2017;42(1):156–77.
125. Lacosta S, Merali Z, Anisman H. Influence of interleukin-1beta on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice. *Psychopharmacology*. 1998;137(4):351–61.
126. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. *Annu Rev Cell Dev Biol*. 2012;28:137–61.
127. Larsson M, Hagberg L, Forsman A, Norkrans G. Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. *J Neurosci Res*. 1991;28(3):406–9.
128. Lei S. Cross interaction of dopaminergic and adrenergic systems in neural modulation. *Int J Physiol Pathophysiol Pharmacol*. 2014;6(3):137–42.
129. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. *Eur J Pharmacol*. 2004;493(1–3):75–83.
130. Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. *Psychopharmacology*. 2003;167(3):315–23.
131. Ling ZD, Potter ED, Lipton JW, Carvey PM. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. *Exp Neurol*. 1998;149(2):411–23.
132. Link VM, Duttke SH, Chun HB, Holtman IR, Westin E, Hoeksema MA, et al. Analysis of genetically diverse macrophages reveals local and domain-wide mechanisms that control transcription factor binding and function. *Cell*. 2018;173(7):1796–1809.e1717.
133. Liu A, Ding S. Anti-inflammatory effects of dopamine in lipopolysaccharide (LPS)-stimulated RAW264.7 cells via inhibiting NLRP3 inflammasome activation. *Ann Clin Lab Sci*. 2019;49(3):353–60.
134. Liu E, Sun J, Yang J, Li L, Yang Q, Zeng J, et al. ZDHHC11 positively regulates NF- κ B activation by enhancing TRAF6 oligomerization. *Front Cell Dev Biol*. 2021;9:710967.
135. Liu X, Nemeth DP, McKim DB, Zhu L, DiSabato DJ, Berdysz O, et al. Cell-type-specific interleukin 1 receptor 1 signaling in the brain regulates distinct neuroimmune activities. *Immunity*. 2019;50(2):317–333.e316.
136. Liu X, Quan N. Microglia and CNS interleukin-1: beyond immunological concepts. *Front Neurol*. 2018;9:8.
137. Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia. *Neuropsychiatry Neuropsychol Behav Neurol*. 1999;12(3):184–92.
138. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
139. Mackie PM, Gopinath A, Montas DM, Nielsen A, Smith A, Nolan RA, et al. Functional characterization of the biogenic amine transporters on human macrophages. *JCI Insight*. 2022;7:e151892.
140. Mandeville JB, Sander CYM, Jenkins BG, Hooker JM, Catana C, Vanduffel W, et al. A receptor-based model for dopamine-induced fMRI signal. *Neuroimage*. 2013;75:46–57.
141. Manza P, Shokri-Kojori E, Demiral ŞB, Wiers CE, Zhang R, Giddens N, et al. Cortical D1 and D2 dopamine receptor availability modulate methylphenidate-induced changes in brain activity and functional connectivity. *Commun Biol*. 2022;5(1):514.
142. Marchetti B, Pluchino S. Wnt your brain be inflamed? Yes, it Wnt! *Trends Mol Med*. 2013;19(3):144–56.
143. Marcondes MCG, Flynn C, Watry DD, Zandonatti M, Fox HS. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. *Am J Pathol*. 2010;177(1):355–61.
144. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. *Nat Rev Immunol*. 2007;7(1):31–40.
145. Martel JC, Gatti McArthur S. Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia. *Front Pharmacol*. 2020;11:1003.
146. Mass E, Nimmerjahn F, Kierdorf K, Schlitzer A. Tissue-specific macrophages: how they develop and choreograph tissue biology. *Nat Rev Immunol*. 2023;23(9):563–79.
147. Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, et al. Microglial responses to dopamine in a cell culture model of Parkinson's disease. *Neurobiol Aging*. 2009;30(11):1805–17.
148. Masyuko SJ, Page ST, Polyak SJ, Kinuthia J, Osoti AO, Otieno FC, et al. Human immunodeficiency virus is associated with higher levels of systemic inflammation among Kenyan adults despite viral suppression. *Clin Infect Dis*. 2021;73(7):e2034–42.
149. Matt SM. Targeting neurotransmitter-mediated inflammatory mechanisms of psychiatric drugs to mitigate the double burden of multimorbidity and polypharmacy. *Brain Behav Immun Health*. 2021;18: 100353.
150. Matt SM, Gaskill PJ. Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. *Brain Res*. 2019;1723: 146398.
151. Matt SM, Gaskill PJ. Where is dopamine and how do immune cells see it? Dopamine-mediated immune cell function in health and disease. *J Neuroimmune Pharmacol*. 2019;15:114–64.

152. Matt SM, Nickoloff-Bybel EA, Rong Y, Runner K, Johnson H, O'Connor MH, et al. Dopamine levels induced by substance abuse alter efficacy of maraviroc and expression of CCR5 conformations on myeloid cells: implications for NeuroHIV. *Front Immunol*. 2021;12: 663061.
153. McNeil LK, Evavold BD. TCR reserve: a novel principle of CD4 T cell activation by weak ligands 1. *J Immunol*. 2003;170(3):1224–30.
154. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. *Cell Commun Signaling*. 2013;11(1):34.
155. Meller E, Bohmacker K, Namba Y, Friedhoff AJ, Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. *Mol Pharmacol*. 1987;31(6):592–8.
156. Mendiola AS, Cardona AE. The IL-1 β phenomena in neuroinflammatory diseases. *J Neural Transm (Vienna)*. 2018;125(5):781–95.
157. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol*. 2004;172:2731.
158. Molina JM, Schindler R, Ferriani R, Sakaguchi M, Vannier E, Dinarello CA, et al. Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). *J Infect Dis*. 1990;161(5):888–93.
159. Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE, et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. *Cell Metab*. 2016;23(1):155–64.
160. Muzio L, Viotti A, Martino G. Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. *Front Neurosci*. 2021;15: 742065.
161. Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. *Nat Neurosci*. 2006;9(8):1050–6.
162. Najera JA, Bustamante EA, Bortell N, Morsey B, Fox HS, Ravasi T, et al. Methamphetamine abuse affects gene expression in brain-derived microglia of SIV-infected macaques to enhance inflammation and promote virus targets. *BMC Immunol*. 2016;17(1):7–7.
163. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. *Biochem Biophys Res Commun*. 2008;373(2):286–91.
164. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. *J Immunol*. 2011;186(6):3745–52.
165. Namba MD, Leyrer-Jackson JM, Nagy EK, Olive MF, Neisewander JL. Neuroimmune mechanisms as novel treatment targets for substance use disorders and associated comorbidities. *Front Neurosci*. 2021;15: 650785.
166. Nazimek K, Strobel S, Bryniarski P, Kozłowski M, Filipczak-Bryniarska I, Bryniarski K. The role of macrophages in anti-inflammatory activity of antidepressant drugs. *Immunobiology*. 2017;222(6):823–30.
167. Nedelcovych MT, Manning AA, Semenova S, Gamaldo C, Haughey NJ, Slusher BS. The psychiatric impact of HIV. *ACS Chem Neurosci*. 2017;8(7):1432–4.
168. Nemeth DP, Quan N. Modulation of neural networks by interleukin-1. *Brain Plast*. 2021;7(1):17–32.
169. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1 β in monocytes and macrophages. *Blood*. 2009;113(10):2324–35.
170. Nickoloff-Bybel EA, Mackie P, Runner K, Matt SM, Khoshbouei H, Gaskill PJ. Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway. *Brain Behav Immun*. 2019;82:239–52.
171. Niu M, Morsey B, Lamberty BG, Emanuel K, Yu F, León-Rivera R, et al. Methamphetamine increases the proportion of SIV-infected microglia/macrophages, alters metabolic pathways, and elevates cell death pathways: a single-cell analysis. *Viruses*. 2020;12(11):1297.
172. Nolan RA, Muir R, Runner K, Haddad EK, Gaskill PJ. Role of macrophage dopamine receptors in mediating cytokine production: implications for neuroinflammation in the context of HIV-associated neurocognitive disorders. *J Neuroimmune Pharmacol*. 2018;14:134–56.
173. Nolan RA, Reeb KL, Rong Y, Matt SM, Johnson HS, Runner K, et al. Dopamine activates NF- κ B and primes the NLRP3 inflammasome in primary human macrophages. *Brain Behav Immun Health*. 2020;2: 100030.
174. Northcutt AL, Hutchinson MR, Wang X, Baratta MV, Hiranita T, Cochran TA, et al. DAT isn't all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling. *Mol Psychiatry*. 2015;20(12):1525–37.
175. Nouhin J, Pean P, Madec Y, Chevalier MF, Didier C, Borand L, et al. Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients. *J Infect*. 2017;74(5):456–65.
176. Nour AM, Yeung YG, Santambrogio L, Boyden ED, Stanley ER, Brojatsch J. Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages. *Infect Immun*. 2009;77(3):1262–71.
177. O'Kusky JR, Boyes BE, Walker DG, McGeer EG. Cytomegalovirus infection of the developing brain alters catecholamine and indoleamine metabolism. *Brain Res*. 1991;559(2):322–30.
178. Okay G, Koc MM, Guler EM, Yabaci A, Kocyigit A, Akkoyunlu Y. The Effect of antiretroviral therapy on IL-6, IL-1 β , TNF- α , IFN- γ levels and their relationship with HIV-RNA and CD4+ T cells in HIV patients. *Curr HIV Res*. 2020;18(5):354–61.
179. Pacheco R. Targeting dopamine receptor D3 signalling in inflammation. *Oncotarget*. 2017;8(5):7224–5.
180. Pacheco R, Contreras F, Zouali M. The dopaminergic system in autoimmune diseases. *Front Immunol*. 2014;5:117–117.
181. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianini M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. *Science*. 2011;333:1456.
182. Parrado AC, Salaverry LS, Mangone FM, Apicella CE, Gentile T, Canellada A, et al. Differential response of dopamine mediated by β -adrenergic receptors in human keratinocytes and macrophages: potential implication in wound healing. *NeuroImmunoModulation*. 2017;24(4–5):282–91.
183. Patola SR, Donohoe G, McKernan DP. Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: a systematic review and meta-analysis. *J Psychiatr Res*. 2023;160:126–36.
184. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? *Neurosci Biobehav Rev*. 2006;30(2):215–38.
185. Pontillo A, Silva LT, Oshiro TM, Finazzo C, Crovella S, Duarte AJ. HIV-1 induces NALP3-inflammasome expression and interleukin-1 β secretion in dendritic cells from healthy individuals but not from HIV-positive patients. *AIDS*. 2012;26(1):11–8.
186. Prinz M, Masuda T, Wheeler MA, Quintana FJ. Microglia and central nervous system-associated macrophages-from origin to disease modulation. *Annu Rev Immunol*. 2021;39:251–77.
187. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. *Nature*. 2010;468(7321):253–62.
188. Regidor DL, Detels R, Breen EC, Widney DP, Jacobson LP, Palella F, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. *AIDS*. 2011;25(3):303–14.
189. Rheinberger M, Costa AL, Kampmann M, Glavas D, Shytaj IL, Sreeram S, et al. Genomic profiling of HIV-1 integration in microglia cells links viral integration to the topologically associated domains. *Cell Rep*. 2023;42(2): 112110.
190. Rice ME, Cragg SJ. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. *Brain Res Rev*. 2008;58(2):303–13.
191. Richfield EK, Penney JB, Young AB. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. *Neuroscience*. 1989;30(3):767–77.
192. Rivera-Escalera F, Pinney JJ, Owlett L, Ahmed H, Thakar J, Olschowka JA, et al. IL-1 β -driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia. *J Neuroinflammation*. 2019;16(1):261.
193. Robinson DL, Venton BJ, Heien ML, Wightman RM. Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. *Clin Chem*. 2003;49(10):1763–73.
194. Rozmyslowicz T, Murphy SL, Conover DO, Gaulton GN. HIV-1 infection inhibits cytokine production in human thymic macrophages. *Exp Hematol*. 2010;38(12):1157–66.

195. Ryan SK, Gonzalez MV, Garifallou JP, Bennett FC, Williams KS, Sotuyo NP, et al. Neuroinflammation and EIF2 signaling persist despite antiretroviral treatment in an hiPSC tri-culture model of HIV infection. *Stem Cell Reports*. 2020;14(4):703–16.
196. Sánchez-Soto M, Casadó-Anguera V, Yano H, Bender BJ, Cai NS, Moreno E, et al. $\alpha(2A)$ - and $\alpha(2C)$ -adrenoceptors as potential targets for dopamine and dopamine receptor ligands. *Mol Neurobiol*. 2018;55(11):8438–54.
197. Sanz JM, Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1 β beta release from microglial cells. *J Immunol*. 2000;164(9):4893–8.
198. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. *Nat Rev Neurol*. 2016;12(4):234–48.
199. Schaale K, Peters KM, Murthy AM, Fritzsche AK, Phan MD, Totsika M, et al. Strain- and host species-specific inflammasome activation, IL-1 β release, and cell death in macrophages infected with uropathogenic *Escherichia coli*. *Mucosal Immunol*. 2016;9(1):124–36.
200. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, et al. Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. *J Neural Transm (Vienna)*. 2010;117(6):699–705.
201. Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. *Behav Brain Res*. 2002;130(1):79–83.
202. Selles MC, Fortuna JTS, de Faria YPR, Siqueira LD, Lima-Filho R, Longo BM, et al. Oxytocin attenuates microglial activation and restores social and non-social memory in APP/PS1 Alzheimer model mice. *iScience*. 2023;26(4):106545.
203. Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, et al. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. *Clin Infect Dis*. 2017;64(2):124–31.
204. Shay T, Jovic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. *Proc Natl Acad Sci U S A*. 2013;110(8):2946–51.
205. Shiau S, Arpad SM, Yin MT, Martins SS. Patterns of drug use and HIV infection among adults in a nationally representative sample. *Addict Behav*. 2017;68:39–44.
206. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, et al. Interleukin-1 β augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. *J Neurosci*. 1993;13(8):3574–81.
207. Sullivan SE, Konradi C. Expression and function of dopamine receptors in the developing medial frontal cortex and striatum of the rat. *Neuroscience*. 2011;199:501–14.
208. Sinclair D, Purves-Tyson TD, Allen KM, Weickert CS. Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain. *Psychopharmacology*. 2014;231(8):1581–99.
209. Sobiś J, Rykaczewska-Czerwińska M, Świętochowska E, Gorczyca P. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. *Pharmacol Rep*. 2015;67(2):353–9.
210. Stojakovic A, Paz-Filho G, Arcos-Burgos M, Licinio J, Wong ML, Mastronardi CA. Role of the IL-1 pathway in dopaminergic neurodegeneration and decreased voluntary movement. *Mol Neurobiol*. 2017;54(6):4486–95.
211. Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. *Basal Ganglia*. 2016;6(3):123–48.
212. Sun Z, Wu K, Gu L, Huang L, Zhuge Q, Yang S, et al. IGF-1R stimulation alters microglial polarization via TLR4/NF- κ B pathway after cerebral hemorrhage in mice. *Brain Res Bull*. 2020;164:221–34.
213. Thompson D, Martini L, Whistler JL. Altered ratio of D1 and D2 dopamine receptors in mouse striatum is associated with behavioral sensitization to cocaine. *PLoS ONE*. 2010;5(6): e11038.
214. Triantafyllou K, Ward CJK, Czubala M, Ferris RG, Koppe E, Haffner C, et al. Differential recognition of HIV-stimulated IL-1 β and IL-18 secretion through NLR and NAIP signalling in monocyte-derived macrophages. *PLoS Pathog*. 2021;17(4): e1009417.
215. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. *J Neurochem*. 2003;87(5):1284–95.
216. Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, Granado N, Moratalla R, Labandeira-Garcia JL. Aging-related dysregulation of dopamine and angiotensin receptor interaction. *Neurobiol Aging*. 2014;35(7):1726–38.
217. Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. *EMBO Mol Med*. 2019;11(6):e10248.
218. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. *Am J Psychiatry*. 2001;158(12):2015–21.
219. Wallet C, De Rovere M, Van Assche J, Daouad F, De Wit S, Gautier V, et al. Microglial cells: the main HIV-1 reservoir in the brain. *Front Cell Infect Microbiol*. 2019;9:362.
220. Walsh JG, Reinke SN, Mamik MK, McKenzie BA, Maingot F, Branton WG, et al. Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. *Retrovirology*. 2014;11(1):35.
221. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. *Brain*. 2004;127(Pt 11):2452–8.
222. Wang T, Nowrangi D, Yu L, Lu T, Tang J, Han B, et al. Activation of dopamine D1 receptor decreased NLRP3-mediated inflammation in intracerebral hemorrhage mice. *J Neuroinflammation*. 2018;15(1):2.
223. Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA. Estradiol effects on the dopamine transporter—protein levels, subcellular location, and function. *J Mol Signal*. 2006;1:5.
224. Wiedlocha M, Marcinowicz P, Krupa R, Janoska-Jazdzik M, Janus M, Debowska W, et al. Effect of antidepressant treatment on peripheral inflammation markers—a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2018;80(Pt C):217–26.
225. Wilkinson KA, Schneider-Luftman D, Lai R, Barrington C, Jhilmee N, Lowe DM, et al. Antiretroviral treatment-induced decrease in immune activation contributes to reduced susceptibility to tuberculosis in HIV-1/Mtb co-infected persons. *Front Immunol*. 2021;12: 645446.
226. Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. *Cell*. 2015;160(1):62–73.
227. Yaseen MM, Abuharfeil NM, Darmani H. The role of IL-1 β during human immunodeficiency virus type 1 infection. *Rev Med Virol*. 2023;33(1): e2400.
228. Ye F, Alvarez-Carbonell D, Nguyen K, Leskov K, Garcia-Mesa Y, Sreeram S, et al. Recruitment of the CoREST transcription repressor complexes by Nerve Growth factor IB-like receptor (Nurr1/NR4A2) mediates silencing of HIV in microglial cells. *PLoS Pathog*. 2022;18(7): e1010110.
229. Yuan L, Liu S, Bai X, Gao Y, Liu G, Wang X, et al. Oxytocin inhibits lipopolysaccharide-induced inflammation in microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice. *J Neuroinflammation*. 2016;13(1):77.
230. Yue S, Wang T, Yang Y, Fan Y, Zhou L, Li M, et al. Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF- κ B signaling pathway. *Int Immunopharmacol*. 2021;96: 107798.
231. Zavala F, Rimaniol AC, Boussin F, Dormont D, Bach JF, Descamps-Latscha B. HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. *J Immunol*. 1995;155(5):2784–93.
232. Zhang L, Mosoian A, Schwartz ME, Florman SS, Gunasekaran G, Schiano T, et al. HIV infection modulates IL-1 β response to LPS stimulation through a TLR4-NLRP3 pathway in human liver macrophages. *J Leukoc Biol*. 2019;105(4):783–95.
233. Zhao ML, Kim MO, Morgello S, Lee SC. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. *J Neuroimmunol*. 2001;115(1–2):182–91.
234. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. *Cell Discovery*. 2020;6(1):36.
235. Zhu H, Lemos H, Bhatt B, Islam BN, Singh A, Gurav A, et al. Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. *PLoS ONE*. 2017;12(9): e0183484.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.